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Introduction 
The course of disease after infection with the hepatitis B virus is very diverse. The 
early manifestations of the disease may be mild and anicteric, more severe with 
jaundice or even fulminant with acute liver failure. Most patients recover comple-
tely. However, in some individuals the virus is not cleared and they become chronic 
hepatitis B virus carriers. It is not well known whether the early course of disease in 
patients who clear the virus is similar to the early course in those who eventually 
become chronic carriers. Some clinical, serological and histological differences 
between the various initial disease periods have been described. For example, a 
mild or asymptomatic early course of disease has been reported to be more 
frequently followed by persistence of the virus than a jaundiced episode. 
Chronic carriers are also not a homogeneous group. A large proportion are 
asymptomatic. They have no biochemical or histological signs of hepatitis. The rest 
of the hepatitis B virus carriers have some degree of chronic hepatitis. This varies 
from mild with little tendency to liver damage to active liver disease with progression 
to liver cirrhosis. Primary hepatocellular carcinoma is relatively frequently found in 
patients with hepatitis B positive liver cirrhosis. Chronic liver failure and hepatocel-
lular carcinoma both may lead to death. 
This clinical spectrum, ranging from complete recovery to death, is the result of 
infection with just one type of virus. Although many subtypes of the hepatitis B virus 
are known, no differences of virulence have become apparent, which suggests that 
differences in clinical course are due to differences in host response. Subjects with 
impaired cellular or humoral immunity, in comparison to apparently healthy sub-
jects, frequently fail to eliminate the virus after infection but usually develop rnllder 
forms of chronic hepatitis. On examination of liver biopsies T -lymphocytes appear 
to be the effector cells in the hepatocytolysis which accompanies viral hepatitis. 
Therefore, the various courses of disease have been ascribed to differences of the 
host's immune response to the viral infection. The immune response may have at 
least two effects: l) (partial) removal of viral products and 2) damage of infected 
liver cells. An adequate immune response results in clearance of the virus. In some 
cases this is accompanied by appreciable liver cell damage and jaundice, in others 
the clearance of the virus occurs without clinical symptoms. In the case of an 
inadequate immune response, with failure to clear the virus, the liver cell damage 
may also vary from severe to completely absent. Elimination of the virus and 
damage to liver cells therefore seem to be mediated by different immunological 
mechanisms. 
It is possible that the course of disease is detennined somewhere between the 
infection and the early symptoms. The key factor may be the efficacy of early viral 
elimination. Theoretically, viral elimination may be the result of l) destruction and 
elimination of all infected liver cells and/or 2) selective intracellular suppression of 
viral replication. The former is a general mechanism of viral elimination. With res-
pect to hepatitis B virus infection there is some doubt as to whether viral elimination 
is the exclusive result of destruction of infected liver cells, as viral elimination and 
liver cell damage do not appear to be congruent in the various clinical forms of 
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hepatitis B. Although there is no clear evidence for specific suppression of hepatitis 
B virus replication, selective suppression of viral replication by antiviral antibodies 
has been described for other viruses. Thus, besides liver cell destruction, selective 
suppression of viral replication could conceivably play a role in the elimination of 
the hepatitis B virus. It is not known at what time during the early disease the see-
mingly dillerent immunological mechanisms mediating viral clearance and liver 
cell damage come into play. Similarly, the factors that influence these immunolo-
gical processes are not welllmown. 
Hepatitis B virus infection causes considerable morbidity and mortality throug-
hout the world. Recently, safe and reliable prophylaxis has become available in the 
form of vaccination. However, despite many efforts, no therapy has been shown to 
be conclusively effective in patients who have developed chronic hepatitis B 
Motivation 
Apart from prophylaxis, effective treatment of chronic hepatitis B is an important 
goal. Rational therapy can only be based on an extensive understanding of the 
disease processes. The mechanism that triggers the development of chronic hepati-
tis B is unknown. Even the factors that determine the efficacy of viral elimination and 
the extent of liver cell damage have been only partially characterized. 
Aim. of the study 
The aim of this study was to find correlations between l) the various courses of 
disease after infection with the hepatitis B virus and 2) quantitative parameters of 
viral replication and liver cell degradation, viral subtypes and the immunological 
response, in order to obtain more insight into the timing and the mechanisms of the 
development of chronic hepatitis B. 
Design 
Patients were grouped according to the several possible courses of disease after 
infection with the hepatitis B virus: 
l) patients with acute hepatitis B; 
2) subjects who had recovered from acute icteric hepatitis B; 
3) subjects who had recovered from acute non-icteric hepatitis B; 
4) chronic hepatitis B virus carriers without hepatitis; 
5) chronic hepatitis B virus carriers with chronic persistent hepatitis; 
6) chronic hepatitis B virus carriers with chronic active hepatitis and 
7) patients who had cleared the hepatitis B virus and had developed chronic 
"auto-immune" hepatitis. 
The study was designed to correlate these various well defined courses of disease 
after hepatitis B virus infection to: 
l) quantitative parameters of viral activity and 
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2) quantitative parameters of liver cell degradation, separately and compared in 
time, in order to obtain information about the course of vtral activity and liver cell 
degradation in patients with early hepatitis B who would eventually have 
different outcomes; 
3) the hepatitis B vtral subtypes and the subtypes of antivtral antibodies, in order 
to estimate the importance of viral factors and the subtype-related aspects of 
humoral immunity; 
4) the peripheral T-cell status, in order to determine possible cellular irnmunore-
gulatory factors; and 
5) the HLA type, in order to establish genetic (irnmunoregulatory) factors predis-
posing the host to a particular course of dtsease. 
The following data were necessary: 
l) Quantitative parameters of hepatitis B virus replication and vtral products in 
time during the early phase of acute hepatitis B; 
2) Quantitative parameters of liver cell damage, simultaneously with the viral 
parameters; 
3) Characterization of subtypes of hepatitis B vtral antigens and antibodies in 
patients with the various courses of acute hepatitis B and chronic hepatitis B 
carriership; 
4) Characterization of irnmunoregulatory T-lymphocyte subtypes in subjects 
with the various courses after hepatitis B virus infection; 
5) Detennination of the (genetic) HLA type in subjects with the various courses 
after hepatitis B virus infection. 
6) Normal control values. 
12 
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2.1 The hepatitis B virus 
The hepatitis B virus (HBV) is a DNA containing virus that mainly replicates in the 
liver cells of man and some higher primates, such as the chimpanzee. The viral 
genome codes for production of infectious virus particles with a diameter of 46 nm 
and a large amount of non-infectious smaller spherical and tubular particles by the 
infected liver cells. The latter are 22 nm in diameter and consist of excess viral coat 
protein, lipids and carbohydrates. The viral coat protein contains the hepatitis B sur· 
face antigen (HBsAg). The HBV itself consists of a nucleocapsid core surrounded by 
an envelope of the HBsAg containing viral coat protein, lipids and carbohydrates. 
The core includes the DNA genome, a DNA polymerase and a capsid protein, bearing the 
hepatitis B core antigen (HBcAg) and the hepatitis B e antigen (HBeAg) (fig 2.1). 
HBsAg 
HBcAg CORE 
HBeAg --------
26 nm 
42 nm 
figme 2.1: The structure and the antigens of the hepatitis B virus. 
Several subtypes of the hepatitis B virus have been described (l ,2), based on dlf. 
ferences in the coat protein. There are four major subtypes: adw, ayw, adr and ayr, 
which have the determinant a in common. The determinants d andy, and w and r 
are mutually exclusive in one subtype. The antigenic dlfferences between the HBV 
strains are well established in epidemiological studies (3), inoculation studies in 
animals (4,5) and DNA sequence studies (6,7). 
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HBV DNA is a small circular molecule. It was first described by Robinson et al. (8). The 
DNA molecule is partly double-stranded, partly single-stranded, with a variable ratio. 
The long strand, or minus strand, has a fixed length of about 3200 nucleotides. The 
length of the short (plus) strand ranges from 50 to 75 per cent of that of the long (minus) 
figure 2.2: Genetic organisation of the hepatitis B virus genome. (Reproduced from 
Tiollas (17), with pennission of the publishers.) 
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strand (9). The plus strand is repaired by a DNA polymerase, using the minus strand 
as a template (10). The complete nucleotide sequence of HBV DNA is known for 
several subtypes of the virus (6,7). The minus strand contains four large open reading 
frames, called the S, P, X and C regions (ll) (fig 2.2). 
The S region codes for the HBsAg related proteins of the vtral envelope. This 
region is divided into the geneS, the pre-S! and pre-S2 sub-regions. The geneS 
region encodes the polypeptides P24 and GP27, both 226 amino acids long, but 
with different glycosylation. Theoretical analysis of the structure of these polypeptides 
has permitted a model for the spatial structure of HBsAg, with hydrophylic and 
hydrophobic regions (12,13). The hydrophylic regions probably bear the antigenic 
detenninants of HBsAg (13). The pre-S2 and pre-S! regions code for minor additional 
polypeptides at the N-terminal side of the gene S polypeptides. These larger forms 
of HBsAg are termed GP3l /GP34 and P39/GP42, respectively ( 14,15), also with dif-
ferent glycosylation. P39 and GP42 have been identified as the translation products 
of the entire preS I geneS reading frame (16). Thus, apart from the subtypes, six 
HBsAg containing polypeptides are known to date. The HBsAg subtypes seem to be 
correlated to slight differences in the amino acid sequences coded for in the gene S 
and the pre-Sl regions (13,17). The relative concentration of the pre-S coded poly-
peptides, in comparison to P24 and GP27, is higher in HBeAg positive than in 
HBeAg negative serum (18). Since HBeAg is correlated with active HBV replication, 
this suggests that the pre-S region is activated in that condition. GP31 and GP34 
probably bear the receptorfor polymerized human serum albumin, which may play 
a role in the penetration of the HBV into the hepatocyte (19). 
The P region is the longest reading frame of the HBV genome, having considerable 
overlap with all other regions. There is some evidence that it codes for the DNA poly-
merase molecule (10). 
The X region encodes a small polypeptide with slight variations according to the 
vtral subtype (6). The functional meaning of the X region is unknown. Antibodies 
against peptide products of this region have been detected in human sera (20). 
The C region codes for the polypeptides of the capsid, which is related to HBcAg 
and HBeAg. These polypeptides are hydrophobic and may play a role in the bin-
ding of the core to the vtral envelope (13). HBeAg occurs as a soluble protein in the 
serum, either free or in association with immunoglobulin G (21 ). 
The HBV DNA can occur in a freely replicating form, which has been detected in 
liver cells as well as in HBeAg positive serum of HBV caniers (22). It can also exist in 
an integrated form in the genome of the hepatocyte. Integrated HBV DNA is mostly 
found in liver cells of HBeAg negative chronic HBV caniers, without active liver 
disease and in hepatocellular carcinoma cells (23,24). ln such cases the S gene 
may come to expression of HBsAg, but no products of the P and C regions are 
observed. 
HBV DNA has also been detected in bone marrow and mononuclear blood cells 
during acute and chronic hepatitis B (25). Other extra-hepatic tissues, such as bile 
ducts, pancreas, spleen, kidney, skin, endothelial and smooth muscle cells, have 
also been found to contain HBV DNA (26,27). 
The replication cycle of hepatitis B-lil::e viruses has been investigated in other 
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viruses of the so-called hepadna virus group (28), the duck hepatitis virus, the 
ground squirrel hepatitis virus and the woodchuck hepatitis virus, which are com-
parable to the human hepatitis B virus and therefore can be used as a model (29). 
The replication cycle ofhepadnaviruses is characterized by the use of an RNA inter-
mediate in the multiplication of the DNA genome (30,31). In these hepatitis B-like 
viruses multiple plus strand RNA copies are produced by the cellular RNA polymerase 
from each minus strand DNA molecule. The RNA intermediates either may serve as a 
template for DNA replication or have messenger function for the viral proteins. The 
RNA precursors of the DNA genome, termed "pre-genomes", are assembled into the 
immature nucleocapsid cores and degradated during reverse transcription of the 
new DNA minus strand. Synthesis of the plus strand DNA starts after completion of 
the minus strand (17,32). 
2.2 Detection of hepatitis B virus products in serum and liver. 
Several serological markers can be used to characterize the clinical stage after 
hepatitis B virus infection. Signs of active viral replication are high titres ofHBsAg as 
well as positive tests for HBeAg, DNA polymerase and HBV DNA in the serum and 
the presence in liver cells of HBcAg, HBeAg and HBV DNA. 
Qualitative detection of the viral antigens HBsAg and HBeAg by sensitive and 
specific radioimmunoassays and enzyme immunoassays is in wide use (33-35). 
Quantitative determination of these antigens, however, usually remains restricted to 
centres with special interest in hepatitis B virus infection (36-39). The absence of 
HBsAg and/or HBeAg does not prove that the serum is non-infectious, since HBV 
infections have been described with HBsAg negative, anti-HBc positive sera ( 40), as 
well as with HBsAg positive, HBeAg negative anti-HBe positive sera (41). 
DNA polymerase activity points to the presence of DNA containing hepatitis B 
virus particles ( 42). DNA polymerase activity is usually found in the sera of patients 
with active viral replication. HBsAg positive sera without DNA polymerase activity 
may contain hepatitis B virus particles, visible by electron microscopy, but these 
particles probably do not contain the complete viral DNA within their cores. If that is 
true, they would be non-infectious (43). However, non-infectivity of HBsAg positive 
sera is very difficult to prove. DNA polymerase activity is detected by counting the 
incorporated radiolabel after inculoation of serum with radiolabeled thymidine in a 
suitable medium ( 44,45). 
Hepatitis B core antigen in serum can be detected by radioimmunoassay. A posi-
tive test is considered to be a sign of active viral replication ( 46). 
Hepatitis B virus DNA in serum is detected by means of molecular hybridization 
techniques. Usually HBV DNA, adsorbed from the serum to a nitrocellulose sheet, is 
hybridized with a HBV DNA probe. Such a probe consists of in vitro produced HBV 
DNA, labeled with an isotope ( 4 7). In a second step the fixed hybridized probe is 
revealed by autoradiography. Like the tests for DNA polymerase, HBcAg and 
HBeAg in serum, the HBV DNA hybridization assay is positive in the case of active 
viral replication. 
Hepatitis B virus antigen localizations in liver tissue are demonstrated with 
immunofluorescence and immunoperoxidase techniques. Specific antibodies 
labeled with fluorescein or peroxidase are inculoated with the liver tissue to bind to 
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the antigens. After washing the tissue slides are examined microscopically. In this 
woy, the expression of HBsAg and HBcAg can be investigated (48-51). HBeAg is 
predominantly found in co-occurrence with HBcAg (52,53). The viral antigen 
expression in liver tissue is believed to be modulated, at least in part, by the host's 
immune defence and to reflect the grade of insufficiency to eliminate the hepatitis B 
virus (54). 
Detection of hepatitis B virus DNA in liver tissue is performed either with extraction 
of DNA from the liver tissue and Southern blotting or with in situ hybridizotion.ln the 
former technique, the extracted DNA is digested with endonucleases, followed by 
electroforesis and molecular hybridization with isotope-labeled DNA (55). This 
technique allows the detection of free HBV DNA as well as HBV DNA integrated in 
the host genome (56-58). The in situ hybridization technique can be applied to 
formalin-fixed liver biopsy specimens. A DNA probe, labeled with an isotope or a 
biotin-avidin-peroxidase complex, is incubated with the liver tissue and in a second 
step the coupe is autoradiographed or examined by microscope, depending on the 
labeling method (26,59). 
2.3 The clinical course after hepatitis B virus infection. 
Various courses of disease moy develop after infection with the hepatitis B virus 
(fig 2.3). The HBV can cause acute icteric hepatitis, non-icteric hepatitis or no 
hepatitis at all. In any of these cases the virus can be cleared, leading to recovery, or 
persist, leading to chronic HBV carriership. Chronic HBV carriers moy be asympto-
matic or develop chronic persistent or chronic active hepatitis, in a mild, moderate 
or severe form. So, in acute disease as well as in chionic carriership various degrees 
of hepatitis are found, inespective clearance or persistence of the virus. The dis-
congruency between liver cell degenerotion and virus elimination suggests that 
these two processes are mediated by different mechanisms. 
Some factors, such as age, sex and immunological status, moy predispose to per-
sistence of the virus. The age at the time of infection is important, as almost all neonates 
develop chronic HBV carriership after infection with the HBV, whereas children and 
adults do so much less frequently (60-63). Sex is also a predisposing factor in adults, 
but not in children (60,61 ). Chronic HBV carriership is about two times more frequent 
in men than in women (63,64). The importance of the immunological status is reflected 
by the high prevalence of chronic HBV carriers in subjects with impaired cellular 
immunity, such as renal dialysis patients, subjects with Down's syndrome and 
patients with lymphoma or leukemia (63,64). It has been observed that a mild early 
course of disease, mostly without jaundice, is relatively frequently followed by persistence 
of the virus and the development of chronic HBV carriership (62,63,65,66). 
Exogenous factors which moy influence the cltnical course after HBV infection 
include concomitant infection with other viruses, of which the Delta agent is possibly 
the most important (67), and exposure to hepatotoxins such as ethanol (68). 
It is estimated that there are about 200 million chronic HBV carriers worldwide 
(64). The frequency of HBV carriers ranges from 15-20% in some countries in Africa 
and Southeast Asia to less than I% in North America and Western Europe. High risk 
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groups for acquiring a HBV infection are discemable in the populations of the 
geographical regions with low overall prevalence, for instance medical personnel, 
intravenous drug abusers and male homosexuals with frequently changing sexual 
contacts. These groups have in common that they are involved in the transmission 
routes of the HBV. 
INFECTION 
Asymptomatic 
BsAg carrier 
figure 2.3: Courses of disease after hepatitis B virus infection. The relative number 
of patients following a certain course is roughly indicated by the width of 
the arrow. 
HBV is usually transmitted by means of blood or blood containing products from 
infectious individuals (69). Transmission may lake place through skin lesions or by 
injections, for instance by a contaminated needle, or through mucous membranes, 
by sexual contact. This person-to-person spread of the virus is termed 'horizontal 
transmission". Another important mode ofHBV transmission is "vertical" spread from 
an infectious mother to her child during pregnancy or at the time of birth (70). 
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The natural history of chronic hepatitis B includes changes in the clinical course, 
accompanied by changes in biochemical and serologic parameters. Three courses 
of disease can be distinguished: 
I) Persistence of chronic active hepatitis and serological markers of viral replica-
tion, HBeAg, DNA polymerase activity and HBV DNA. 
2) Disappearance of these markers from the serum and seroconversion from 
HBeAgto antibodies againstHBeAg (anti-HBe) (71-74). The seroconversion may be 
preceded by a period of obvious reactivation of the hepatitis activity (75). Following 
HBeAg seroconversion, the liver disease becomes asymptomatic. HBsAg rematns 
present or may be serologically cleared as well. As discussed in section 2.1, HBV 
DNA is suspected to be integrated in the liver cell genome in this type of 
patients (23,24). 
3) Initial disappearance of the serological markers of viral replication and 
seroconversion to anti-HBe, but subsequently reactivation of chronic active hepatitis with 
reappearance of markers of viral replication (76,77). In a group of patients with this 
course of disease the mean age was older compared to patients with the first or 
second type of disease, and the liver disease was of longer duration with a higher 
prevalence of cirrhosis (77). The cause of reactivation is unknown, but it has incidentally 
been observed after immunosuppressive chemotherapy (76), antiviral chemofherapy, 
major systemic bacterial infections and surgery (78). 
The three courses of disease have been described to occur in 59,29 and 12% of 
chronic hepatitis B cases, respectively (78). 
Simultaneous presence of HBsAg and antibodies to HBsAg (anti-HBs) has been 
described in single case reports of chronic hepatitis B. In our patients £his phenomenon 
was found in 32 out of 89 patients (36%), as dicussed in chapter N (79). In each 
instance anti-HBs seemed to be directed to another subtype of HBsAg than that 
present in the same serum. These findings have been confinned by others 
(78,80, 81). 
Approaches to treatment of chronic hepatitis B mainly comprise immune modula-
ting and antiviral therapy. 
Immune modulating therapy is based on fhe assumption !hat humoral and cellular 
mechanisms may play an essential role in the clearance of the virus and in the 
pathogenesis of liver cell degeneration. From this point of view, immunosuppressive 
therapy might be effective in suppressing liver cell damage, as has been described 
for chronic non-viral hepatitis (82). However, immunosuppression has been shown 
to be ineffective in chronic hepatitis B (83,84), probably because of continuing 
synthesis of viral products.lmmunostimulation theoretically might improve fhe clearance 
of fhe virus, but in practice £his has not been shown; the course of disease even worsened 
in some patients because of increased hepatitis activity (85). 
Antiviral therapy includes interferons, adenine arabinoside and acyclovir. In 
some patients a temporary suppression of viral replication can be achieved. Mono-
therapy with these agents has not shown to be efficacious over a longer period of 
time (74,86,87). The effect of combination of antiviral drugs is being studied 
(88). 
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2.4 Mechanisms of liver cell degeneration and viral elimination. 
The occurrence of viral replication and continuing liver cell damage show a close 
temporal relationship in one clinical condition, the period of reactivation of liver 
disease preceding HBeAg seroconversion in chronic active hepatitis, as described 
in section 2.3 (71· 77). This relationship suggests a causal role of active viral replication in 
the pathogenesis of liver cell degeneration in this condition. However, in various 
other clinical courses of disease there is a discrepancy between viral replication 
and liver cell degradation, indicating that the amount of HBV in liver and serum 
does not correlate with the severity of the hepatitis (77,89). Therefore, the HBV itself 
does not seem to be directly cytopathic (89,90) and another mechanism is probably 
involved in the pathogenesis of HBV induced liver cell damage. 
Several observations point to the cellular immune system as a mediator of liver 
cell damage in hepatitis B (91 ): on microscopic examination of liver biopsies the 
necrotic liver cells appear to be surrounded by T lymphocytes, which are assumed 
to cause the liver cell necrosis (92); patients with defective cellular immunity more 
frequently become chronic HBV carriers after HBV infection (93), but they usually 
have only minor or no activity of chronic hepatitis (63); reactivation of hepatitis 
activity has been described to occur during immunosuppressive chemotherapy as 
well as after discontinuation of such therapy (76,90); stimulation of cellular immunity 
in chronic. HBV carriers is reported to increase the liver cell necrosis (94,95). 
Humoral immunity does not seem to be closely related with liver cell necrosis, 
since patients with agammaglobulinemia may develop severe acute and chronic 
hepatitis (96) and infusion of large doses of anti-HBs does not result in increased 
liver cell necrosis (97,98). 
The mechanism by which the cellular immune system causes chronic liver cell 
necrosis has been studied from several hypothetical starting-points. The "classical" 
theory assumes that T-cell cytotoxicity is evoked by the expression of HBV-
associated antigens on the liver cell surface, a mechanism that requires dual recognition 
of viral and self (HLA-) antigens on the target cells (99).1n this theory, chronic hepatitis B is 
the result of insufficient viral clearance and continuing expression of viral antigens. 
HBcAg-like expression on the liver cell membrane is especially found in the case of 
chronic active, HBeAg positive, hepatitis (100, 101). Cytotoxic T lymphocytes with 
HBcAg specificity have been described in patients with this kind of disease (l 02). 
These cells may therefore play a role in hepatocytolysis. Antibodies to HBcAg (anti· 
HBc), bound to the HBcAg-like determinant on the cell surface (101), may perhaps 
modulate the cytotoxic attack by covering the infected cells (l 02). 
Other theories assume that the primary defect in chronic hepatitis is related to the 
immunoregulation of lymphocytotoxicity, either by stimulation of antibody· 
dependent cellular cytotoxicity by antibodies attached to liver-specific lipoprotein 
antigens (LSP) on the liver cell surface (103), or by immunoregulatory molecules, 
originating from necrotic liver cells or lymphocytes (104).1n these theories, chronic 
hepatitis B is not necessarily the result of persistence of viral replication, but rather 
the effect of changes in liver cell membranes or immunoregulatory lymphocytes. 
In attempts to answer these questions, many investigations have been performed 
on general cellular immune function, the cytotoxic lymphocyte function and the 
suppressor cell function in hepatitis B (91 ). A major problem of these tests is the lack 
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of an experimental in vivo or in vitro model that has sufficient congruence with the 
different courses of hepatitis B. The studies on general immune function in hepatitis 
B have produced divergent results with respect by lymphocyte sensitization and 
transformation by HBV antigens, other antigens and mitogens (l 05). Alterations 
found in cytotoxic lymphocyte function have been interpreted as the result of 
increased T lymphocyte cytotoxic function, antibody-dependent cellular cytotoxicity or 
natural killer (NK) cell activity. Defective suppressor cell function is presumed to be 
a regulatory factor in enhanced cytotoxic activity (1 06). Many types of suppressor 
cell activity assays have been used to study this issue. Although the results of these 
non antigen-specific assays are heterogeneous, there is a tendency to decreased 
suppressor cell activity in patients with chronic active hepatitis B, but a significant 
correlation with the disease activity has not been found (91 ). 
The interpretation of these immunologic function tests remains difficult, because 
the methods are indirect and artefacts cannot be excluded. A main artefact in the in 
vitro tests seems to be the NK cell activity. NK cells in low concentrations already 
have a profound effector function and overshadow the T lymphocyte cytotoxic 
function and the antibody-dependent cellular cytotoxicity for which the tests were 
designed (91). In one study (107) lymphocytes of chronic HBV carriers showed 
enhanced aspecilic cytotoxicity against a series of epithelial,fibroblastoid,lympho-
blastoid and myeloid cell lines. The effector cells had properties of NK cells. 
However, the degree of NK cytotoxicity did not correlate with the degree of hepatitis. 
Thus, the importance ofNK cell cytotoxicity in the pathogenesis of liver cell damage 
in vivo remains uncertain and the marked in vitro effects of NK cells should probably 
be regar ded as artefacts. 
Direct characterization of the phenotypes of immunoregulatory peripheral T 
lymphocyte subpopulations by means of monoclonal antibodies has revealed a 
slight tendency to a decreased number of suppressor cells in vartous forms of chro-
nic hepatitis Bas well as in early acute hepatitis B (91). In two studies (108,109) 
lowest numbers of T suppressor cells occurred in HBeAg negative chronic active 
hepatitis B patients. This finding may indicate that ongoing liver disease activity 
after (partial) clearance of the virus is caused by cytotoxic activity against liver cell 
constituents rather than HBV antigens (1 09), as discussed in chapter V of this study. 
These investigations on T -cell phenotype have some limitations. The peripheral cir-
culating T-cell subsets can only reflect major alterations in the immunoregulatory 
status of the patients, and may be different from the local situation in the liver. The 
phenotypic expression of the T -cells has no clearly defined correlation with T -cell 
function (91 ). The subsets are detected by monoclonal antibodies which do not dis-
tinguish between suppressor and cytotoxic T -cells. Similarly, the functional display 
in the subpopulation with helper/inducer phenotypic expression is not homogeneous. 
The Major Histocompatibility Complex, the Human Leucocyte Antigen system in 
man, is involved in the regulation of the immune response. The class I HLA antigens 
are maialy recognized by T -cells that have the ability to develop into cytotoxic cells. 
Class II antigens play a role in the activation of regulatory T lymphocytes and 
cooperation between those and other cells of the immune system (110). Therefore, 
several investigators have looked for a possible relationship between HLA and the 
course of disease after HBV infection (111). These studies have not provided con-
clusive evidence for an association between HLA and HBV infection, chronic 
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HBsAg carriership or HBsAg positive chronic active hepatitis, probably in part 
because of the divergent patient groups studied and the numbers of HLA antigens 
tested. In chapter VI a study is presented which examines the relationship between 
the different courses of disease and both HLA class I and class II antigens. 
Viral elimination may be an important factor determining the course of disease. 
Although HBV is not thought to be directly cytopathic, a close relationship has been 
established between viral replication and continuing liver cell degeneration, as dis-
cussed in sections 2.3 and 2.4. Moreover, a role for HBV in the continuation of liver 
disease is suggested by the observation that immunosuppressive therapy is not 
effective in chronic hepatitis B, in contrast to otherforms of chronic hepatitis (83,84). 
Therefore, in addition to a study of the immunologic mechanisms of liver cell 
degeneration, it is important to obtain insight into the mechanism of viral elimination 
in acute and chronic hepatitis B. 
Antibodies against HBV antigens may play an important role in viral clearance. 
Freely circulating virus particles are neutralized and prevented from infecting liver 
cells by anti-HBs, as shown by the efficacy of anti-HBs after vaccination with HBsAg 
in preventing HBV infection. A similar effect has been ascribed to anti-HBV 
antibodies which are distinct from anti-HBs (anti-Dane antibodies) (112,113). Re-
infection of liver cells by HBV released from infected cells is also possibly prevented 
in this way. Anti-Dane antibodies can almost never be detected in the serum of 
patients with chronic active hepatitis B (113). The absence of these antibodies 
would allow chronic re-infection of hepatocytes. The possible modulating effect of 
anti-HBc on the cytotoxic attack to infected liver cells has been mentioned above 
(101,102). Finally, it is possible that antiviral antibodies may suppress the intracellular 
HBV production, as dicussed below, but this mechanism remains hypothetical. 
Two main hypotheses have been formulated regarding HBV elimination from 
infected liver cells. In the first hypothesis, the virus is eliminated by destruction of all 
infected liver cells by means of a cytotoxic mechanism (99). The second hypothesis 
assumes that antiviral antibodies may suppress the synthesis of viral proteins, without 
necessarily destroying all infected liver cells (104). The first mechanism is a general 
mechanism of viral elimination. With hepatitis B this mechanism would imply that 
the degree of liver injury is dependent on the number of infected liver cells. 
However, observations in chimpanzees (114-116) and man (117) have revealed 
that the majority of liver cells are already infected with HBV in the early phase of 
acute hepatitis B. All observed cases recovered normally without massive liver cell 
necrosis. It is difficult to believe in these instances that viral elimination has occurred 
only by destruction of all infected liver cells. In the second hypothesis different 
immunologic mechanisms are proposed for viral elimination and liver cell necrosis. 
Although such mechanisms remain hypothetical for hepatitis B, suppression of viral 
replication by antiviral antibodies on the cell surface has been described for measles 
(118-120), Epstein-Barr virus (121) and herpes simplex virus (122). The hypotheses 
concerning viral elimination are discussed in chapter III, in connection with a study 
on viral elimination in acute hepatitis B. 
Despite all attempts to synthesize the vast amount of information on hepatitis B 
virus elimination and liver cell destruction (91,123-126), firm conclusions cannot be 
drawn. Further studies are needed to supply missing data and resolve apparently 
conflicting observations. 
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CHAPTER ill 
VIRUS ELiliJ.IlNATION IN ACUTE HEPATITIS B; 
RECOVERY VERSUS CHRONIC HEPATITIS 
The contents of this chapter have been submitted for publication under the same 
title, with the following authors: J. van Hattum, S.W. Schalm, F.J.W. ten Kate and 
R.A. Heijtink 
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Summary 
The disappearance of viral antigens in relotion to liver cell destruction was studied in 
63 potients with acute hepotitis B. Hepotitis B virus DNA, DNA polymerase activity, 
HBeAg and HBsAg were measured quantitatively in serum, and viral antigens were 
determined in liver biopsies by immunofluorescence. All data were related in time to the 
alanine aminotransferase (ALI) peak as a marker of maximum liver cell destruction. 
Six months after initial symptoms 53 patients had recovered and l 0 had become 
chronic HBsAg carriers. At the onset of disease no differences in viral antigens were 
observed between the two groups with different outcome. In patients who 
recovered, the HBsAg and the HBeAg levels decreased significantly from two weeks 
prior to the ALI peak onwards. The disappearance of HBeAg and HBsAg occurred 
independently of the extent of the liver disease. HBV DNA, DNA polymerase and 
viral antigens in liver biopsies were mainly detectable before and around the ALI 
peak In potients who developed chronic hepotitis, viral antigens in the serum and 
liver tissue remained consistently high. 
These findings indicate that the final course of the acute hepotitis B is set at least 
two weeks before the maximum hepotitis activity and that quantitative assays of 
HBsAg or HBeAg appear to be early indicators of prognosis. The disappearance of 
viral markers, prior to and independently of the extent of liver cell necrosis, suggests 
that suppression of the viral protein synthesis is an additional mechanism of virus eli-
mination, apart from destruction of infected liver cells. 
Introduction 
Disappearance of virus multiplication is the hallmark of recovery from a hepatitis 
B virus (HBV) infection. Chronic hepatitis B is characterized by continuous synthesis 
of viral proteins, with or without liver cell damage. Better understanding of the mec-
hanism which underlies the suppression or elimination of virus replication may pro-
vide a rational basis for the treatment of chronic viral hepotitis. 
The two main hypotheses concerning the mechanism of virus elimination in acute 
hepatitis B differ with respect to the role of liver cell destruction. According to the first 
hypothesis the virus is eliminated by destruction of all infected liver cells (l ). The 
second hypothesis suggests that antiviral antibodies may suppress the synthesis of 
viral proteins without necessarily destroying all infected liver cells (2) (see 
chapter II). 
The aim of this investigation was to study viral markers and liver cell destruction 
quantitatively in time during the early phase of acute hepatitis Bin order to find dif-
ferences in the courses of viral markers between patients who would recover and 
those who would become chronic hepatitis B virus carriers, and to obtain additional 
information about the mechanism of hepatitis B virus eliminotion. 
Patients and methods 
Patients 
Sixty-three consecutive potients, admitted because of acute hepotitis B, were eligible 
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for this study. They fulfilled the following criteria: no history, symptoms or signs of 
liver disease prior to presentation; alanine aminotransferase (ALT) at least 2 x upper 
limit of normal for 5 days or more; hepatitis B surface antigen (HBsAg) and immune 
globulin M antibody to core antigen (IgM-antiHBc) positive; liver biopsy confirming 
the presence of acute vtral hepatitis without signs of chronic hepatitis; neither trnmu-
nosuppressive drugs nor general anaesthesia during the four weeks prior to the 
initial symptoms of hepatitis. Fifty-three patients recovered (group I) with loss of 
HBsAg and normalization of ALT. Chronic hepatitis developed in l 0 patients (group 
II), in whom HBsAg and elevation of the ALT level persisted for more than six months. 
A second liver biopsy confirmed chronic hepatitis B. 
The majority of patients who had been referred to our ward by the family doctor 
(3!/33) was classified in group I, whereas stx of the lO patients who had been referred 
after routine testing for HBsAg by the bloodbanl::, ended up in group II. This pattern 
of referral may explain the relatively high number of patients that developed 
chronic hepatitis. 
Twenty-seven patients of group I and 6 patients of group II were admitted in an 
early phase of the disease, with ALT and bilirubin values still increasing (group Ia 
and Ila, respectively). In such cases the exact date of maximum ALT elevation (ALT 
peak) could be determined. Twenty-nine patients of group I and four patients of 
group II were admitted at or after their ALT peak. We observed no differences between 
the patients who were admitted before ALT peak and those who were admitted at or 
after ALT peak, regarding age, sex and time intervals from the onset of symptoms to 
some characteristic points in the courses of ALT, bilirubin, HBeAg and HBsAg (table 
3.1 ). Evidently, all patients were admitted before, at or only a few days after their real 
ALT peak. The time intervals are not applicable to group II, because most patients of 
this group had a low-grade hepatitis without jaundice. 
Methods 
Blood samples were drawn weekly during the period of acute hepatitis and for stx 
weeks after the ALT peak had occurred and then monthly for six months. Serum ALT 
and bilirubin levels were determined by standard methods; sera were stored at -
20°C until determination of serologic HBV markers. Radiotrnmunoassays (Abbott 
Laboratories, Chicago, ill., USA) were used for the detection of HBsAg (AUSRIA II) 
and HBeAg. HBeAg was quantified by the ratio of the radioactivity of a test sample 
to that of a negative control (PIN ratio) for sera diluted 1:10. Sera with a PIN ratio 
below 2.1 were retested undiluted. Diluted sera were considered negative when 
their PIN ratio was less than 1.7, corresponding to 2.1 for undiluted sera.HBsAgtitres 
were measured by reverse passive haemagglutination tests (AUSCELL, Abbott 
Laboratories, Chicago, ill., USA) in two-fold dilution series. DNA polymerase activity 
was determined according to the method of Howard (3). Hepatitis B virus DNA (HBV 
DNA) was detected by dot hybridization using the HBV DNA probe pCP 10 after 
labeling by nick translation (See also chapter II). The HBV DNA probe was kindly 
provided by Dr. C. Brechot lnstitut Pasteur, Paris. lgM anti-HBc was determined by 
an ELISA-technique, after preincubation of serum samples on anti-lgM coated microliter 
plates (Organon, Oss, The Netherlands). 
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Liver biopsies were reviewed by two independent observers. Direct immunofluo-
rescence microscopy was performed using commercial HBsAg-antiserum (Central 
Laboratory of the Netherlands Red Cross Blood Transfusion Service, The Nether-
lands) and an HBcAg-antiserum obtained from a patient recovering from acute 
hepatitis B, lacking other hepatitis B markers. The number of positive fluorescent 
hepatocytes was expressed as a percentage of all liver cells. 
All data concerning the HBV markers were related in time to the date of the 
ALT peak 
Statistical analysis was performed with rank sum (Wilcoxon) tests and Spear-
man's correlation tests. 
Results 
Viral markers and the course of acute hepatitis B. 
In the early phase of acute hepatitis B the courses of viral proteins were measured 
in patients who recovered (group I) and in those who became chronic HBV caaters 
(group II). The courses of serum HBeAg, HBsAg and ALT are presented in figure 3.1. 
Two weeks prior to the ALT peak, the HBsAg and HBeAg titres of patients in group I 
were in the same range with those of group II. However, at the time of the ALT peak 
the HBsAg titre had exponentially dropped in group I patients, thus becoming 
significantly different from the HBsAg level found in patients of group II (p < 0.05). 
The same course was observed for the HBeAg level; it also dropped exponentially 
in patients of group I, becoming significantly lower (p < 0.05) than the HBeAg level 
in group II at the time of the ALT peak. In patients who developed chronic hepatitis 
the HBsAg titre and the HBeAg PIN ratio remained consistently high during the 
observation period. At the time of the ALT peak, 9 out of 53 patients from group I 
already had a negative HBeAg assay but none of the patients had a negative 
HBsAg assay. In patients who recovered, HBeAg disappearance occurred within 
9.5 weeks after the ALT peak (95% confidence upper limit). 
HBV DNA assays were done with the remaining sera from a limited number of 
patients. In group I 36 sera from 16 patients were tested. Early sera were obtained 
prior to or in the week of maximal ALT. Mostly an early and a later serum sample 
were tested per patient. In the early period lO out of 16 serum samples (six out of 12 
patients) were positive for HBV DNA. In the later period only two out of 20 serum 
samples (two out of 13 patients) were positive (figure 3.2) In the HBV DNA positive 
samples HBeAg PIN ratio ranged from 3.4 to 29.8 (mean 16.3) and HBsAg titre ranged 
from 800 to 6400 (mean 3200). In 13 out of the 24 sera negative for HBV DNA the 
HBeAg test was still positive with a PIN ratio from 1.7 to 22.2 (mean 5.4). In group II 
all four patients tested for HBVDNA were positive at one or two occasions during the 
observation period. 
DNA polymerase activity was detectable (with a low PIN ratio of 1.4 to 1.6) in only 
four out of 12 patients of group I at the time of the ALT peak. 
The mean maximum ALT level for group I (1766 U!l) was much higher than that of 
group II (365 U/l) (p < 0.01) (table 3.1, figure 3.1). In all patients who developed 
chronic hepatitis (group II), serum bilirubin levels were always lower than twice the 
upper limit of normal and no jaundice was observed. 
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Figure 3.1 The courses of HBeAg PIN ratio, HBsAg titre and ALT in acute hepatitis B 
for patients who recovered (•) and those who developed chronic 
hepatitis (o). In patients who recovered the HBeAg PIN ratio and the 
HBsAgtitre dropped significantly two weeks before the ALT peak At the 
time of the ALT peak there was a significant difierence in HBeAg level, 
HBsAg titre and ALT level between the two groups (*: p<0.05; 
**: p<O.Ol) HBeAg-sera were diluted 1: 10; PIN ratios below 1.7 were 
considered to be negative. 
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Figure 3.2 HBV DNA in acute hepatitis B for 16 patients who recovered (•) and 4 
patients who developed chronic hepatitis (o). In patients who 
recovered, 10 out of 16 early samples, obtained at or before week zero, 
were positive for HBV DNA, but only two out of 20 later samples were 
HBV DNA positive. 
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Figure 3.3: The presence of HBV antigens in liver tissue during acute hepatitis Bin 
patients who recovered (•) and those who developed chronic hepatitis 
( o). The relative number of liver biopsies that showed positive anti-HBs 
and/or anti-HBc immunofluorescence is shown for three biweekly 
periods. 
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TABLE 3.1 Characterization of patients with acute hepatitis who recovered (group I) and those who 
developed chronic hepatitis (group m:k 
recovery chronicity 
group totOl adffilss1on ad!riission totCrl adinission actmission 
prior to after prior to after 
ALTpeak ALTpeak ALT peak ALTpeak 
number 53 27 26 10 6 4 
General features: 
Age (yrs) 30.2±10.6 30.7± 11.8 29.7±9.1 27.8±5.8 30.5±5.1 23.8±4.3 
Sex (MJFJ 40/13 2017 20/6 8/2 5/1 3/1 
Severity of disease: 
Peak ALT (IJ/1) 1766±1166 1928±969 1598±1322 366±198 349±161 389±241 
Bilirubin peak (lffilol/1) 227±142 225±129 229±154 16±6 15±5 17±7 
HBeAg (PIN ratio)** 8.1±7.4 8.9±7.8 7.6±7.5 24.8±6.5 26.8±9.3 23.5±3.4 
HBsAg (titre)~ 4.0±1.4 3.9± 1.3 4.2±1.7 5.7±0.8 5.8±0.5 5.7±0.9 
Time intervals (weeks): 
onset of symptoms to 
peakALT 3.3±2.4 3.4±2.2 3.1±2.3 rLO. n.a. n.a. 
onset of jaundice to 
peakALT 1.8±1.5 1.7± 1.0 1.8±1.8 n.a_ n.a. n.a. 
peak ALT to ALT lxN+ 6.9±2.8 6.7±3.0 7.4±2.6 n.a. n.a. n.a. 
peak ALT to HBeAg § 
negative 2.3±4.3 1.8±3.6 2.8±5.0 n.a. n.a. n.a. 
peak ALT to HBsAg § 
negative 7.0±3.9 8.0±4.1 5.5±3.6 n.a. n.a. n.a. 
• : atamean ± . 2 o),•* : HBeAg ratio and HBsAg titre at fue time of fue ALT peak HBsAg titre given as log (titre) x 100. 
: N: upperhnlltofnonnol + 
§ : RIA negative for nndiluted sera. 
n.a. : not applicable. 
The results of immunofluorescence studies using hepatitis B antisera on liver biopsies 
are shown in figure 3.3. The number of biopsies with more than 5% hepatocytes that 
exhibited specific anti-HBs and/or anti-HBc fluorescence was highest among the 
biopsies taken early in the course of acute hepatitis B. In group I positive anti-HBs 
immunofluorescence was always seen at the liver cell membrane and never in the 
cytoplasm In three patients more than 50% of the liver cells exhibited membranous 
immunofluorescence.ln one case nuclear anti-HBc staining was seen in 65% of the 
liver cells. The biopsies of group II always exhibited strongly positive membranous 
immunofluorescence, and in 6 cases there was also some cytoplasmatic reaction 
with anti-HBs. 
Viral markers and liver cell degeneration. 
In patients who recovered (group I) the above mentioned data were also used to 
study the course of liver cell damage in relation to the quantitative course of viral 
proteins. ALT and bilirubin were tested as indices of liver damage. The bilirubin 
peak corresponded well in time with the ALT peak (mean bilirubin peak one day 
after ALT peak, SD: 5 days). ALT was used as marker of liver damage in this 
presentation. 
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The markers of viral protein synthesis were measured quantitatively or semi-
quantitatively and their courses were compared to the course of ALT. HBVDNA and 
DNA polymerase activity appeared to become negative at the time of the ALT peak, 
followed by HBeAg at 3 weeks (SD: 3 weeks) and HBsAg at 7 weeks (SD: 4 weeks). 
The courses of HBeAg and HBsAg could be measured quantitatively reasonably 
well. Both the HBeAg and the HBsAg levels decreased already rapidly in the two 
weeks prior to the ALT peak (fig. 3.1 ). 
In order to study a possible relationship between the extent of liver cell degeneration 
and the amount of viral proteins we compared the following parameters to each 
other. The ALT peak, the time interval from ALT peak to normal ALT and the product 
of the ALT peak and the time interval from ALT peak to normal ALT (area under ALT 
curve) were each compared to the HBeAg PIN ratio at the time of the ALT peak, the 
time interval from ALT peak to negative HBeAg test and the area under HBeAg 
curve. The same was done for ALT and the HBsAg curve. The individual data were 
used in paired tests. No statistically significant correlation was found. 
Discussion 
In this study quantitative measurements of viral activity and liver cell degeneration 
were performed simultaneously. It therefore was possible to study the courses of 
these parameters during acute hepatitis B and to compare them in relation to a time scale. 
We found that in the early phase of acute disease HBeAg and HBsAg significantly 
decreased in those patients who eventually recovered. The viral parameters DNA 
polymerase, HBV DNA, HBeAg and HBsAg each seemed to have their own elimination 
pattern. The sequence of disappearance, as observed in our series was l) DNA 
polymerase/HBV DNA, 2) HBeAg, 3) HBsAg. The disappearance of HBeAg and 
HBsAg occurred independently of the extent of liver desease. 
Other studies on the quantitative course of viral parameters of acute hepatitis Bin 
man usually have been restricted to one viral antigen at a time. Barker et al.(4) 
demonstrated a decreasing HBsAg titre before clinical hepatitis in 69 patients. 
Krugman et al.(5) confirmed this observation in 4 patients. Aldershvile et al.(6), who 
followed 45 patients with HBeAg-positive acute hepatitis type B, found clearance of 
HBeAg from the peripheral blood within l 0 weeks after initial symptoms of hepatitis 
in recovering patients. Four patients with persistence of HBeAg for more than !0 
weeks all became HBsAg carriers. Our results show that HBeAg disappeared within 
9.5 weeks from the ALT peak (95% confidence limit), which is about 13 weeks after 
the onset of symptoms. In our observations, quantitative measurement of HBeAg 
(which has not been described in acute hepatitis) shows that HBeAg, like HBsAg, 
starts decreasing prior to clinical symptoms. Alberti et a!. (TJ found very low and 
decreasing DNA polymerase activity prior to the ALT peak for 8 patients with acute 
hepatitis B who recovered. Our findings are in accordance with these results. The 
higher sensitivity of the HBV DNA determination compared to DNA polymerase 
activity elongated the time of observation of Dane par tide markers with l-2 weeks. 
A recent study on fulminant hepatitis B showed that serum HBV DNA disappeared 
prior to HBeAg (8). The same order was observed in our patients, who had a normal 
course of disease with recovery. 
In our study, patients who recovered exhibited a significant decrease of the 
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HBeAg PIN ratio and the HBsAg titre in the two weeks before as well as after the ALT 
peak. Furthermore, there was a statistically significant difference in HBeAg and 
HBsAg levels at the time of the ALT peak between patients who eventually 
recovered and those who developed chronic hepatitis B. These patients all had 
high levels ofHBeAg and HBsAgthat did not decline during the observation period. 
Quantitative measurement of HBsAg and HBeAg levels therefore seems to be sensitive 
and practical for the prognosis of acute hepatitis B. The final course of acute hepatitis B 
appears to be set at least two weeks before the ALT peak, and with the aid of HBsAg 
titres and/or HBeAg quantification the prognosis can be determined early in the 
course of disease. Such an early indicator of prognosis might be useful if therapeutic 
intervention with interferon or other drugs is considered for those patients who fail to 
clear HBV antigens in the first weeks of an acute hepatitis B. 
£n view of the hypothesis that viral elimination is caused by destruction of virus 
containing liver cells (1), we compared the disappearance curves for several viral 
parameters with the biochemical curve of liver cell degeneration, using ALT as the 
most specific marker. First we observed that the viral parameters HBeAg and HBsAg 
were disappearing exponentially while liver cell degeneration increased slowly, 
reaching its maximum about two weeks later (figure 3.1 ). Secondly, we found no 
correlation between the decline in the serum markers of viral protein production and 
the serum markers of liver cell necrosis (table 3.1 ). These findings do not fit easily 
with the hypothesis that viral elimination in acute hepatitis B results predominantly 
from elimination of infected liver cells. £n addition, we as others (9,10,11 ,12) observed 
patients with a normal benign course and recovery who exhibited positive HBV 
immunofluorescence in upto 100% of their liver cells. £n these cases recovery with 
complete virus elimination occurred. This could not have been achieved solely by 
destruction of all infected liver cells, because there were no signs of massive liver 
cell necrosis. 
Our findings are thus better compatible with the hypothesis of Edgington and 
Chisari (12), who suggest that viral elimination early in the course of acute hepatitis 
B can also be the result of suppression of the viral genome in the infected liver celL 
Such a mechanism remains hypothetical as far as hepatitis B is concerned, but 
suppression of viral replication by antiviral antibodies has been described for measles 
(13,14,15), Epstein-Barr virus (16) and herpes simplex virus (17). The sequential 
disappearance of viral antigens can now be explained, especially since there is no 
evidence that this feature is due to different half-life times of HBeAg and HBsAg. The 
available data suggest that the half-life of HBsAg is about 2.5 days (18). 
On the basis of the above-mentioned arguments the decreasing serum levels of 
viral markers are unlikely to result solely from liver cell destruction. Suppression of 
viral protein synthesis may be an additional mechanism of viral elimination. 
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CO-OCCURRENCE OF HBsAg AND ANTI-HBs; 
TWO CONSECUTIVE INFECTIONS OR A SIGN OF 
ADVANCED CHRONIC LIVER DISEASE? 
The contents of this chapter have been published in the J oumal of Medical Virology 
1982; 10: 83-90, under the same title and with the following authors: R.A Heijtink, 
). van Hattum, S.W. Schalm, N. Masurel. Reproduced with permission of the 
publishers. 
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Summary 
Simultaneous presence of HBsAg and anli-HBs was detected in 32 out of 89 
Dutch chronic hepatitis B virus carriers of Caucasian race. The subtype frequencies 
and the distribution of risk factors for acquiring a hepatitis B virus infection were 
compared in the chronic HBV carriers and 38 patients with acute hepatitus B who 
recovered. In the chronic HBV carriers, HBsAg was subtyped ad in 28 and cry in four 
cases. Anli-HBs could be subtyped in 25 cases using reference antigens discrimi-
nating between d, y, and w l-w4 determinants. In 20 out of these 25 patients HBsAg 
subtype ad (HBsAg/ad) was accompanied by antibody to determinant y (anti-y), 
whereas HBsAg/ay and anti-d were simultaneously detected in the serum of one 
patient The antibody patiem in sera from the remaining patients was complex. In 
the acute hepatitis B group, HBsAg was sub typed cry in 25 and ad in 13 cases. Thus, 
in our patients a predominance of cry was found in acute hepatitis with recovery and 
ad in chronic HBV carriers. This difference was partly caused by the prevalence of 
cry in drug-users and ad in homosexuals. Non-drug users appeared to have an 
equal chance to acquire HBsAg/ad or HBsAg/ay acute hepatitis. 
Eighteen anli-HBs positive chronic HBV carriers were matched for age, histology, 
and HBeAg status with 18 anti-HBs negative chronic HBV carriers. No differences in 
risk factors for acquiring a hepatitis B infection were found. These results do not sup-
port the hypothesis that co-occurrence of HBsAg and anli-HBs is due to two con-
secutive infections with hepatitis B virus. The frequency of the co-occurrence of 
HBsAg and anli-HBs was found to be related to the degree of progressive liver 
disease, since anti-HBs was found in three out of 23 asymptomatic HBV carriers, in 
four out of 20 chronic persistent hepatitis B patients, in 20 out of 41 chronic active 
hepatitis B patients, and in all five patients with chronic active hepatitis B and 
cirrhosis. The high frequency of anli-HBs in patients with advanced liver disease 
may be the result of a disturbed irrununologic response mechanism. 
Introduction 
Simultaneous presence of hepatitis B surface antigen (HBsAg) and antibodies 
against antigenic determinants of HBsAg ( anli-HBs) has recently been described in 
single cases of HBsAg-positive chronic liver disease by vartous authors (l-8). 
Since several subtypes of the hepatitis B virus are known (9,1 0), co-occurrence of 
HBsAg and anli-HBs may be explained by two subsequent infections with different 
subtypes, one of which gives rise to hetero-typic antibodies ("two infection hypothesis") (3) .. 
Alternative mechanisms, also presented by Le Bouvier et al. (3), are: I) the presence 
of "hidden" determinants on HBsAg which cause antibody formation without sub-
sequent interaction with HBsAg-bearing particles; 2) some form of persistent double 
infection with HBV of two different genotypes, while one or the other antigenic pro-
duct is "outweighed" by its monospecific subtypic antibody at the lime of blood 
sampling; and 3) quasi-monospecific antibody, evoked by an antigenic stimulus 
unrelated to HBV infection. Of our group of 89 HBsAg-posilive chronic hepatitis 
patients, 32 (36%) showed HBsAg as well as anli-HBs in their sera. This offered the 
opportunity for a more detailed investigation of the relation between HBV 
antibodies and HBV antigens, and to establish the validity of the widely accepted 
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"two infection hypothesis". For the latter reason we also compared the subtype 
frequencies and the distribution of risk factors for acquiring a HBV infection in 
patients with acute and chronic hepatitis. 
Patients and methods 
Patients 
The study group consisted of 89 chronic HBV carriers and 38 patients with acute 
symptomatic hepatitis Band complete recovery. Eight patients of the chronic group 
had been observed with acute symptomatic hepatitis B and subsequently had 
developed chronic hepatitis, as described in chapter Ill All patients were born of 
Dutch parents of Caucasian race. 
The patient group with biopsy-confirmed chronic HBV carriership was divided 
into 4 subgroups: I) asymptomatic HBV carriers (AC) (n=23); II) chronic persistent 
hepatitis B ( CPH) (n = 20); lli) chronic active hepatitis B ( CAH) (n =41); IV) CAH with 
cirrhosis (CIRR) (n =5). Patients were grouped according to standard histologic criteria 
(11) and the following supplementary criteria: AC: HBsAg positive> 6 months, no 
symptoms of liver disease, serum alanine amino transferase (ALT) continuously nor-
mal > 6 months; CPH: HBsAg positive > 6 months, ALT < 2 x upper ltrnit of normal; 
CAH: HBsAg positive > 6 months, ALT > 2 x upper limit of normal. 
Acute hepatitis B was diagnosed if a patient was HBsAg positive and showed ALT 
> 5 x upper limit of normal for a period of at least 5 days and a liver biopsy in confomrity 
with acute viral hepatitis. 
From the initial group of 89 chronic patients, 18 anti-HBs negative patients could 
be matched with patients in the anti-HBs positive group for histology, HBeAg/anti-
HBe status, and, in the majority (13 cases), for year of birth (divided in 5-year 
periods). The number of patients that could be matched was limited, due to the limited 
number of HBeAg positive/anti-HBs negative patients with chronic active hepatitis 
(group lll), and the lack of anti-HBe positive/anti-HBs negative patients with 
cirrhosis (group IV). 
Methods 
The sera were stored at -20 'C after collection. Radioimmunoassays (Abbott 
Laboratories, Chicago, Ill., USA) were used for the detection ofHBsAg (AUSRIAII), 
anti-HBs (AUSAB), HBeAg, and anti-HBe (ABBOTT-HBe). 
Subtyping of HBsAg and anti-HBs was performed according to the method of 
Hoofnagle et al. (12). This method is based upon the neutralization of anti-HBs by 
HBsAg in solution prior to the performance of the AUSAB test The residual amount of 
anti-HBs is then compared with the original amount detected using HBsAg and anti-
HBs negative normal human serum as additive. Before incubation of anti-HBs positive 
sera with reference antigens of known sub type or of anti-HBs reference sera with 
HBsAg positive sera, pilot experiments were conducted to assure an optimal ratio of 
antibody in the neutralization reaction. In all cases of subtyping of HBsAg in anti-
HBs positive sera, HBsAg was present in a relatively large concentration, so that the 
serum could be diluted until the contribution of the patient's anti-HBs was 
negligible. 
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For the sub typing of HBsAg we used guinea pig antisera containing anti-ad and 
anti-cry, which were incubated with human HBsAg/ay and HBsAg/ad, respectively, 
to obtain antisera specific for d and y (an ti-d, anti-y). The reference antigen- and 
antibody containing sera were kindly supplied by the National Institutes of Allergy 
and Infectious Diseases, Bethesda, Md., USA. After subtyping anti-HBs in some 
HBsAg positive sera, monospecific an ti-d and anti-y serum became available. Sub-
typing ofHBsAg with these reagents was in accordance with the results obtained by 
monospecific antibodies prepared in vitro. Subtyping of anti-HBs was made possible by 
reference sera kindly supplied by Dr. A.M Courouce-Pauty (Centre National de 
Transfusion Sanguine, Paris, France). The antigen subtypes used in the neutralization 
reaction were: aywl, ayw2, ayw3, ayw4, adw2, and adw4. 
The results were expressed as the percentage of reduction of counts per minute 
(cpm) measured in the AUSAB test after preincubation with antigen compared to 
preincubation with normal human serum. A percentage of more than 50 was considered 
positive. The results were reproducible within 10%. In the case of subtyping HBsAg, the 
reduction was always less than 10% or more than 60%, dependent on the subtype of 
the monospecific antiserum used. 
Results 
Subtype of HBsAg 
In the group of 32 patients with anti-HBs positive sera, HBsAg was subtyped ad in 
28 and ay in four cases. The number of d versus(vs) y determinant positive sera (15 
vs 3) in the matched anti-HBs positive group was not significantly different from that 
in the matched anti-HBs negative group (17 vs 1) (chi-square with Yates' correction: 
0281, P'0.50). 
Subtype of anti-HBs 
Antibodies could ·be subtyped in 25 out of the 32 anti-HBs positive sera. In the 
remaining seven cases insufficient material was available, or the concentration was 
too low (cpm < 5x negative control value in AUSAB test). In the latier cases anti-HBs 
was repeatedly positive in the same serum sample or could be detected in the same 
concentration in other samples of that particular patient In Table 4.1 the results of 
anti-HBs subtyping are grouped according to antibody patiem. In the majority of 
cases (20 of 25) HBsAg/ad was accompanied by anti-y antibodies as the sole type 
of antibody. One patient combined HBsAg/ ay with anti-d. This patient had probably 
been infected in Southeast Asia during a 2-year stay. 
In two cases the only type of antibody detected was anti-w3, in one patient 
accompanied by HBsAg/ay and in the other by HBsAg/ad. The two remaining 
cases exhibited a rather complex patiem: HBsAg/ad : anti-y and anti-w4 (adw4) 
and HBsAg/ad: probably anti-w2 (ayw2), anti-w3 (ayw3) and anti-w4 (ayw4). 
The results of the neutralization tests on the serum of patient no.24 illustrate that 
the affinity of antibodies for the reference antigens is not uniform. The percentage of 
reduction with subtypes ayw 1 (53%) and adw4 (52%) remained unchanged if the 
concentration of these antigens was changed eightfold. 
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TABLE 4.1 Neutralization of anti-HBs by reference antigens in 25 HBsAg containing sera 
Percentage neutralization by HBsAg subtype 
Patient no. HBsAg 
subtype aywl ayw2 ayw3 ayw4 adw2 adw4 
I ad 97 98 97 94 0 9 
2 ad 61 71 72 71 2 0 
3 ad 97 98 96 96 0 0 
4 ad 95 98 96 90 3 4 
5 ad 85 96 90 88 I 8 
6 ad 91 97 95 91 4 0 
7 ad 61 63 98 80 11 13 
8 ad 99 100 100 95 0 0 
9 ad 99 98 98 100 0 0 
10 ad 94 92 100 89 20 5 
11 ad 86 95 94 80 0 0 
12 ad 92 97 96 99 6 7 
13 ad 85 98 93 96 0 0 
14 ad 93 96 93 93 6 6 
15 ad 100 100 100 95 7 0 
16 ad 90 97 98 100 0 0 
17 ad 98 99 99 99 0 13 
18 ad 56 75 63 75 6 8 
19 ad 99 99 89 95 8 13 
20 ad 85 93 95 89 3 0 
21 ay 0 0 0 31 56 95 
22 ad 11 7 89 29 21 30 
23 ay 20 10 66 30 32 17 
24 ad 53 94 96 100 15 52 
25 ad 0 100 100 95 0 38 
Risk factors 
The 18 matched anti-HBs positive and anti-HBs negative patients were grouped 
according to their risk factors for acquiring a hepatitis B infection (Table 4.2). In 
about half of the cases a risk factor could not be found for both the anti-HBs positive 
and the anti-HBs negative groups. In the other half, the risk was almost equally dist-
ributed among the two groups. For comparison, the risk distribution for the whole 
group of anti-HBs positive patients is added to Table 4.2. 
TABLE 4.2 Risk factor dismbution among anti-HBs positive (anti-HBs +)and anti-HBs negative (anti-
HBs -) chronic HBV carriers 
matched groups 
total group 
anti-HBs + anti-HBs- anti-HBs + 
Drug abuse 0 I I 
Homosexuality 4 5 6 
Multiple transfusions I 0 3 
Medical profession 0 I I 
Relatives with HBsAg 3 3 4 
No risk factor 10 8 17 
Total 18 18 32 
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Subtype frequencies and risk factors compared in chronic and acute hepatitis B 
Since the number of HBsAg/ad and HBsAg/ay antigens and the risk factors are 
almost equally distributed among the groups of anti-HBs positive (n = 32) and anti-
HBs negative (n = 18) chronic patients, these groups were combined and a com-
parison was made of subtype distribution and risk factor with the group of 38 acute 
hepatitis B patients who recovered. 
Table 4.3 illustrates that HBsAg/ad predominated in chronic HBV carriers (90%) 
and HBsAg/ay in acute hepatitis (66%).ln one case of the acute hepatitis group with 
recovery, a combination of HBsAg/ay and anti-d had been detected during the 
acute hepatitis. The development of chronic liver disease was observed in eight 
cases with acute hepatitis, as described in chapter III.ln all cases except one, the 
subtype was HBsAg/ad; twice anti-HBs (subtype anti-y) was already present in the 
first sample with HBsAg obtained during the acute hepatitis. 
With regard to risk factors, drug abuse was predominantly found in patients with 
acute hepatitis and recovery, whereas homosexuality and contact with relatives 
was mostly observed in patients who had developed· chronic hepatitis. 
TABLE 4.3 Risk factor distribution in cases of chronic HBV carriers and acute hepatitis B patients sub· 
divided according to subtype of HBsAg 
chronic acute 
ad ay ad ay 
Drug abuse I I I II 
Homosexuality II 0 2 2 
Multiple transfusions 3 0 I I 
Medical profession I I 2 0 
Relatives with HBsAg 6 I 0 I 
No risk factor 23 2 7 10 
Total 45 5 13 25 
Anti-HBs in relation to histology and HBe status 
The frequency of anti-HBs positive sera in four groups of patients with different stages 
of liver disease is given in Table 4.4. The percentage of anti-HBs positive sera 
increased with the severity of the liver disease. Anti-HBs was found most frequently 
in HBeAg positive sera (20 out of 34, 59%) but this was probably due to the association of 
HBeAg with chronic active hepatitis. 
TABLE 4.4 Frequency of antJ>HBs in 89 patients with different stages of chronic HBV carriership and 
their HBeAg and anti·HBe status ("") 
Histology 
I AC 
ll CPH 
ill CAH 
N CIRR 
Total 
anbAiBs+ 
3/23 (13%) 
4/20 (20%) 
20/41 (49%) 
5/5 (100%) 
32/89 (36%) 
HBeAg+ 
anti-HBe-
0/0 
1/2 
19/32 
0/0 
20/34 
HBeAg- HBeAg+ HBeAg-
anti-HBe+ anti-HBe+ anti-HBe-
3/23 0/0 0/0 
2/17 Ill 0/0 
1n 0/0 0/2 
5/5 0/0 0/0 
11/52 Ill 0/2 
*: frequency given as anti-HBs positive I anti-HBs positive and anti-HBs negative patients. 
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Discussion 
Our attention was drawn to the phenomenon of anti-HBs in HBsAg positive chronic 
hepatitis after observing a rise in anti-HBs titer in a patient participating in a double-
blind trial with human leucocyte interferon in CAH patients (l3,l4).ln this patient, 
who received a placebo, HBsAg titer, DNA polymerase activity and HBeAg titer 
decreased concomitantly with the rise of anti-HBs. Approximately one year later, 
three other participants (one treated patient and two control patients) showed anti-
HBs transiently, while maintaining HBsAg. 
ln agreement with other studies, it seemed possible that our HBsAg positive/anti-
HBs positive patients had been infected on two consecutive occasions by different 
subtypes of HBV. In order to find additional evidence for the "two infection hypothesis" 
(3), we determined the HBsAg subtypes in a population of chronic and acute 
hepatitis patients. Predominantly HBsAg/ad was found in chronic HBV carriers, in 
accordance with the observations in neighbouring countries (15-18). In contrast, 
HBsAg/ay prevailed in acute hepatitis. This discrepancy, which was also found by 
others ( l 7,19 ,20) is generally atirtbuted to the predominance of HBsAg/ ad in earlier 
days and the association of HBsAg/ ay with intravenous drug abuse at present. 
However, seven out of eight acute hepatitis cases that subsequently became chronic 
showed the subtype HBsAg/ad in our observation during the last years. Moreover, in 
the acute hepatitis group that recovered the non-drug users appeared to have had 
an equal chance to acqutre HBsAg/ad or HBsAg/ay acute hepatitis, but the 
prevalence of HBsAg/ay in drug-associated hepatitis was confirmed in our study. 
This limited number of observations suggest that the course after an HBsAg/ad or 
HBsAg/ay infection may be different in our country and that the predominance of 
HBsAg/ad in chronic hepatitis is not associated with the prevalence ofHBsAg/ad in 
earlier days. 
It is still conceivable that the presence of HBsAg/ ad and HBsAg/ ay viruses in the 
Dutch population makes it possible to acquire two consecutive infections with different 
subtypes in the absence of trnmunity after the first infection. However, the infection 
rate of hepatitis B is very low in the Netherlands (3.5 per l 00,000). For a patient who 
once has contracted a hepatitis B infection, the chance to acquire a second infection 
seems to be extremely small. It might be argued that the chance for a chronic carrier 
to be exposed for the second time cannot be compared with that of a primary infection 
in the population as a whole, since in about half of the chronic cases risk factors for 
acqutring hepatitis B may be present. We therefore expected a higher frequency of 
risk factors among chronic HBsAg carriers with anti-HBs. However, the prevalence of 
risk factors in HBsAg positive/ anti-HBs negative chronic hepatitis was similar. This 
finding and the observation of increasing frequency of anti-HBs with progressive 
liver disease seem hardly compatible with the "two infection hypothesis". 
We also considered the possibility that both determinants d and y are present on 
complete HBsAg-bearing particles. One of the determinants would then be 'bidden". 
The immune system would only produce both subtypes of antibodies if incomplete 
HBsAg particles, possibly with both detenninants exposed, are released into the 
circulation, for example when liver cells are destroyed by active inflammation. 
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However, this hypothesis is not supported by chemical and enzymatic treatment of 
HBsAg (21 ). Furthermore, the genetic base for antigenic differences between HBV 
strains is well established in epidemiological studies (16), inoculation studies in 
animals (22,23), and DNA sequence studies (24-26). 
Another explanation for the simultaneous presence of HBsAg and anti-HBs may 
be a host-dependent abnormality in the inrmune response. The development of 
chronic hepatitis is ascribed to a (combination of) inadequate antibody response 
and a defect in T-cell function (27,28). However, the detection of HBsAg-specific 
immune complexes (29,30) in chronic hepatitis B patients suggests the existence of 
an antibody response to HBsAg in such cases. Since the frequency of anti-HBs with 
progressive liver disease in our study parallels that of HBsAg-specific circulating 
immune complexes (29,30), it may be suggested that the presence of ''heterotypic" 
soluble anti-HBs, which at least in vitro can be neutralized by heterotypic HBsAg, 
represents a "nonspecific" part of the immune response. Some support for this 
hypothesis is found in an earlier study (31 ), where 16 of our HBsAg positive chronic 
active hepatitis patients were vaccinated with an equine influenza A virus. In 13 
(80%) patients a significant rise was observed against a number of nonrelated 
influenza A strains, while in large vaccination trials with influenza virus nonspecific 
(heterotypic) antibody formation is observed normally only in about 5% (32). 
Since in this study the formation of heterotypic antibodies was observed for HBV 
as well as inlluenza A virus in a relative large number of patients with chronic hepatitis B, 
and anti-HBs was also found frequently by others in such patients (33) and in HBsAg 
positive fulminant hepatitis (34), we suggest an underlying principle of qualitative 
deficiency in inrmune response of the host with degrees in severity leading to different 
forms of hepatitis. 
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Su:m:ma:ry 
The course of disease after hepatitis B virus infection is probably detennined by 
the cellular immune response of the host, which is parlly regulated by the T helper 
and T suppressor cells. hnmunoregulatory T -cell subsets were counted in the peripheral 
blood of 97 patients with various courses after hepatitis B virus infection: 23 of these 
patients were asymptomatic HBsAg carriers without detectable liver disease, 13 
had chronic persistent hepatitis B, 19 had chronic active hepatitis B (ll HBeAg, 8 
anti-HBe ), 7 had chronic active hepatitis with anti-HBs, and 35 were healthy controls 
with anti-HBs after recovery from acute hepatitis B. Peripheral blood mononuclear 
cells were specifically labeled with monoclonal Leu-! (T-cells), Leu-2a (T 
suppressor/cytotoxic cells), andLeu-3a (T helper cells) antibodies and analyzed by 
flow cytometry. 
Leu-3a/Leu-2a ratios for patients with persistence of the virus did not differ from 
those found for patients who cleared the hepatitis B virus. These findings suggest 
that elimination of hepatitis B virus as such is unlikely to be related to the relative 
number of peripheral T -cell subsets. However, evidence was found that the number 
of T suppressor cells had decreased in the subgroup of patients with ongoing chronic 
active hepatitis and anti-HBe. This subgroup of patients who develop chronic active 
hepatitis after partial clearance of the virus probably have an enhanced immuno-
reactivity compared with those running the commoner courses of this disease. 
Introduction 
The extremely variable course of disease after infection with hepatitis B virus 
(HBV) is usually explained by differences in the immunological host response to the 
hepatocytes carrying viral antigens (1,2). These immunological reactions may be 
regulated by T lymphocyte subpopulations, especially T helper and T suppressor 
cells (3), as discussed in chapter II, section 2.4. Several authors have observed differen-
ces in peripheral T-cell subset activity among patients with various forms of chronic 
hepatitis (4-7). The results of these T -cell activity assays are not homogeneous, but a 
tendency is perceivable to decreased suppressor cell activity in patients with chronic 
active hepatitis B. Few data are available on T lymphocyte subpopulations in 
patients with various forms of hepatitis B (8). We therefore studied T lymphocyte subsets 
in the peripheral blood of patients with and without virus elimination and with and 
without chronic hepatitis after hepatitis B virus infection. 
Patients and methods 
Patients. 
One hundred and twenty-four patients with a hepatitis B infection, all of Dutch 
extraction and Caucasian race, were eligible for the study. Reliable T -cell subset 
counts could be obtained in 97 cases. The patients were grouped in accordance 
with standard criteria (9): 23 asymptomatic HBsAg carriers without biochemical or 
histologic abnormalities (AC-B), 13 patients with chronic persistent hepatitis B 
(CPH-B), 19 with chronic active hepatitis B (CAH-B), 7 with chronic active hepatitis 
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after elimination of hepatitis B antigens (CAH-anti-HB), and 35 healthy controls without 
clinical or biochemical abnormalities and with demonstrable anti-HBs after 
recovery from acute hepatitis B (C-anti-HB). 
Methods. 
HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc were determined by radioimmuno-
assays (Abbott Laboratories, Chicago, ill., USA). Mononuclear cells were isolated 
by Ficoll-Isopaque gradient centrifugation by the method of Boyum (10), washed 
twice, suspended in a medium consisting of 25% fetal calf serum, 65% RPM!, and 
10% dimethylsulfoxide, frozen to -80 oc in a polystyrene box, and stored in liquid 
nitrogen. Subsequently, vials with frozen mononuclear cells were thawed to 37 oc 
and, after being washed, were resuspended in 5% bovine serum albumin in 
phosphate-buffered saline. Cell counting was accomplished with a Coulter counter. 
The yield of mononuclear cells was 75%, according to cell counts obtained before 
isolation and after thawing. The cell suspension was diluted to a concentration of l 0 
million cells/mi. One hundred microliters of the suspension were incubated with l 
microgram of fluorescein isothiocyanate-labeled (FTTC) anti-Leu antibodies (Becton 
Dickinson Monoclonal Antibody Center, Sunnyvale, Va., USA) or 5 microlitre of a 
ffiC-labeled goat anti-human Ig antiserum diluted 1:15 (GAH/Ig/F1TC, Nordic 
Immunological Laboratories, Tilburg, TheNetherlands). A dtrect immunofluorescence 
technique was thus applied. The cells were analyzed for the presence ofLeu-1, Leu-
2a, Leu-3a and lg determinants on the cell membrane. Anti-Leu-! is directed 
against a non-subtype specific human T-cell antigen, anti-Leu-2a against a human 
T cytotoxic I suppressor cell antigen, and anti-Leu-3a against a human T helper I 
inducer cell antigen. GAH/Ig/ffiC detects human B lymphocytes and monocyies, 
the latter via the Fe receptor. After incubation for 30 min and washing at 4 °C, the 
cells were analyzed by flow cytometry. 
flow cytometry analysis was performed with a fluorescence-activated cell sorter 
(FACS II, Becton Dickinson FACS Systems, Sunnyvale, Calif., USA). For each sample 
at least l 0,000 cells were analyzed. Percentages of positive cells were calculated 
by plotting the histogram profiles for both unlabeled and ffiC-anti-Leu-antibody 
labeled cells. Viable and nonviable cells could be distinquished on the basis of 
their low-angle scatter characteristics (11). In this manner three groups of mononu-
clear cells could be distinguished (Fig.!): a group with a low scatter signal that 
appeared to consist of nonviable cells (according to a propidium iodide stain) and 
two other groups consisting of viable lymphocytes and monocytes. 
The fluorescence histogram was measured twice, first for all cells and subsequently 
for the viable lymphocytes (Fig.!). When samples contained more than 75% dead 
cells, the lymphocyte window could not be localized exactly, resulting in a less 
precise counting of the lymphocyte subpopulation; this was encountered in 27 
cases. The data for these 27 out of 124 patients were not included in the analysis. 
These patients were equally distributed among the various patient groups. 
Statistical analysis was performed with the Wilcoxon rank sum test (12) and the 
rank correlation test (13); results were considered significant when the p value was 
less than 0.05. 
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Figure 5.1. Typical example of flow cytomefiy analysis of mononuclear cells by 
fluorescence-aativated cell sorter. With forward light scatter three 
groups of mononuclear cells can be distinguished in arbitrary units: 
nonviable cells with a low scatter signal (1-2), viable lymphocytes (2-3) 
and viable monocytes with a higher scatter signal (3-4). By measuring 
the fluorescence, specifically labeled cells can be distinguished at a 
higher level (6-7) than the unlabeled cells. The lymphocyte window (Jy-w) 
separates viable lymphocytes from other mononuclear cells. The histogram 
(right) shows the number of cells with a certain fluorescent intensity. By 
comparing the histogram of a cell population before (b) and alter (a) 
specific labeHng, the percentage of labeled cells can be calculated. 
Results 
In all patient groups we found a statistically high correlation (p < 0.00 I) between 
the distribution of the lymphocyte subpopulations obtained by counting the viable 
lymphocytes only and that found by counting all cells. In these patients approximately 
45% of the cells were viable and 55% were nonviable. 
The distribution of the T-cell subset population, as presented in Table I, is based 
on the counting of viable lymphocytes. We found average values of 56% Leu-] positive 
cells, 19% Leu-2a positive cells, and 40% Leu-3a positive cells, there was close corres-
pondence between the sum of the T-cell subsets and the total T-cell percentage. 
Regarding viral elimination, the T -cell subset counts of the patients who had cleared 
the virus (C-antiHB and CAH-antiHB) were compared to those of patients with persistence 
of the virus (AC-B, CPH-B and CAH-B together). No statistical differences were 
found between these two categories of patients. 
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TABLE 5.1 Distribution of monuclear cells in patients with various courses of disease after hepatitis B 
virus infection 
Patient n~ all* %"- % % % % 3aha group leucocytes monocytes B*cells Leu*1 Leu-2a Leu-3a 
Healthy HBsAg 
carriers 23 5.6±1.3 4.7±2.6 28±13 54±15 18±10 41±12 2.8±1.5 
Chronic persistent 
hepatitis B 13 5.7±1.0 8.1±6.0 23±10 52±10 20± 7 37± 9 2.1±1.1 
Chronic active 
hepatitis B 19 6.2±1.1 5.3±3.9 26±19 55±18 17±8*'!<* 41±14 2.9±1.4 
Chronic active 
hepatitis non-B 
+anti-HBs 7 4.9±1.1 3.9±2.3 31±16 54±14 17± 8 39±12 3.1±2.0 
Healthy controls 
recovered from 
hepatitis B 35 7.4±2.3 6.0±4.8 26±14 60±12 21± 7 42±12 2.4±1.4 
,. 
mean absolute number ± 1 SD (x 1 o- ) per rnm blood 
·~ mean± 1 SD 
*·lrl· P < 0.05 in comparison to healthy controls 
With respect to liver cell damage, the patient groups were compared separately. 
Although there was a considerable range in the percentages of cells, the Leu-2a 
positive (suppressor/cytotoxic) cells were significantly reduced (p < 0.05) in 
patients with chronic active hepatitis B (CAH-B) compared with healthy controls 
who had recovered from hepatitis B (C-antiHB). Patients of the CAH-B subgroup 
with anti-HBe exhibited a more pronounced reduction in Leu-2a positive cells (p < 
0.02), whereas the concentration of these cells was normal in the subgroup with 
HBeAg (Table 2). The patients in the CPH-B andAC-Bgroups, all with anti-HBe, had 
normal T-cell subset concentrations. The number of Leu-2a positive cells in the 
seven patients with chronic hepatitis after virus elimination ( CAH -antiHB) was as 
low as that found for the CAH-B group, but in this small patient group a 5% sig-
nificance was not reached (0.05 < p < 0.10 in comparison with healthy 
controls). 
Comparison of 24 patients with a high Leu-3a/Leu-2a ratio (75-100 percentile) 
with 24 patients with a low ratio (0-25 percentile) yielded no differences in age, sex, 
blood group, HLA, or bilirubin and ALT levels. 
TABLE 5.2 T Lymphocyte subpopulations and HBeAg I anti*HBe status in patients with chronic 
active hepatitis B 
HBeAg 
anti*HBe 
Controls 
* mean±1SD 
n-
II 
8 
35 
-i'* P < 0.02 in comparison to controls 
Discussion 
%Leu-2a* 
19±7 
14±3-
21±7 
%Leu-3a 
39±14 
44±17 
42±12 
3a/2a 
2.5±1.1 
3.4±1.7 
2.4± 1.4 
This study was designed to investigate patients with an HBV infection who diffe-
red in their subsequent HB elimination and liver cell destruction. 
55 
chapter V 
Since elimination of the virus is thought to be mediated by immune responses, as 
discussed in detail in chapter II, section 2.4, we hypothesized a difference in 
immunoregulatory T-cell subsets between patients who had cleared the hepatitis B 
virus and. those with persistence viral. Combining the patient groups in this respect, 
we found no statistical differences between these groups, indicating no general 
defect in immunological host response as cause of viral persistence. Obviously, with 
the methods used a HBV related antigen specific immunologic defect cannot 
be excluded. 
Regarding liver cell degeneration by studying the various courses of disease 
separately, we found a decreased number of T suppressor/ cytotoxic cells in the 
peripheral blood of patients with chronic active hepatitis B. This effect, however, is 
due to the subgroup which had partly eliminated the HB virus (CAH-B with anti-
HBe), confirming the results of Thomas et al.(S). The T-cell subset counts for patients 
with other forms of chronic HBV carriership (AC-B, CPH-B, and CAH-B with persisting 
HBeAg) did not show statistically significant differences compared to the controls. 
Patients with chronic active hepatitis and clearance of the HB virus (CAH-anliHB) 
tended to have a lowernumber ofT suppressor/ cytotoxic cells, but this was not statistically 
significant for the small number of patients studied These results suggest that elimination 
of hepatitis B virus is not causally related to the relative number ofT helper and T 
suppressor cells in the blood. The persistence of active inflammation of the liver after 
partial or total clearance of the virus, however, might be mediated by a high T 
helper/T suppressor cell ratio. 
In fact, the CAH subgroup with anti-HBe is a group of patients with an unusual 
course of disease. Most patients with chronic hepatitis B become biochemically and 
histologically inactive after conversion to anti-HBe (14-16) (see also Chapter II, section 
2.3). The continuing chronic active hepatitis in CAH-B patients with anti-HBe might 
therefore be related to ongoing immunoreactivity against hepatocytes facilitated 
by a low level of suppressor cells. The same mechanism of liver cell desiruction 
might be operational in patients with chronic active hepatitis after clearance of viral 
antigens (CAH-antiHB), although a conclusion is prohibited by the small number of 
patients in this group. Based on these observations, patients with chronic active 
hepatitis B who continue to have high hepatitis activity after seroconversion from 
HBeAg to anti-HBe may theoretically be served by immunosuppressive therapy, in 
contrast to CAH-B patients with a more regular course of disease (17,18). 
Alternatively, chronic active hepatitis might affect the number of T suppressor 
cells. However, the normal number of Leu-2a cells in CAH patients with HBeAg in 
the blood, also observed by Thomas et al. in studies with OKT monoclonal 
antibodies (13), does not support this explanation. 
The results of counting T -cell subsets by means of monoclonal antibodies should 
be interpreted cautiously, since the antigenic properties of the T-cell surface do not 
correspond directly to the functional classification of these cells. One problem of 
interpretation concerns the fact that Leu-2a positive cells are not a homogeneous 
group, since Leu-2a specific antibodies react not only toT suppressor cells but also 
to cytotoxic T lymphocytes. The low number of peripheral Leu-2a positive cells 
might therefore be due to a decreased number of peripheral cytotoxic T lymphocytes, 
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caused by an accumulation of cytotoxic T-cells in liver tissue. Immunohistologic 
analysis of the inflammatory infiltrate in chronic active hepatitis shows predominantly OKT-
8 reactive cells (that is, T suppressor cells and/or cytotoxic T lymphocytes) in the 
liver (19). However, it is unknown whether long-term depression of the suppressor/ 
cytotoxic cells in the blood can be explained by the accumulation of these cells in 
the liver. 
In conclusion, the peripheral blood T-cell subsets investigated in chronic HSV 
carriers do not differ significantly from those in patients who cleared the virus. 
Reduced numbers ofT suppressor/cytotoxic cells were found in patients with persistence 
of chronic active hepatitis after cessation of active viral replication. This finding suggests 
that liver cell destruction in these patients is no longer a direct consequence of the 
hepatitis B virus infection but is mediated by an imbalance among immunoregulatory 
T-cells. 
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HLA ANTIGENS IN PATIENTS WITH VARIOUS 
COURSES~RHEPATITISBVIRUSmffECTION 
The contents of this chapter have been submitted for publication, under the same 
title, with the following authors: J. van Hottum, G.M Th. Schreuder, S.W. Schalm. 
59 
chapter~ 
Sununary 
In order to find a possible relationship between the course of disease and the 
phenotype frequency of HLA determinants, 396 Dutch subjects of Cancasian race 
were studied. Six groups of individuals with various courses after HBV infection were 
compared to healthy controls. The hepatitis B patients were grouped according to 
standard criteria: l) 4 7 had recovered from acute symptomatic hepatitis B, 2) 60 
had recovered from asymptomatic hepatitis B, 3) 26 were asymptomatic HBV car-
riers, 4) 16 had chronic persistent hepatitis B, 5) 37 had chronic active hepatitis B 
and 6) l 0 had chronic active hepatitis after elimination of hepatitis B antigens. 29 
Class I and 13 Class II HLA-antigens were assayed by standard microlympho-
cytotoxicity tests. 
The phenotype frequency of the Class II antigen DQwl appeared to be sig-
nificantly lower in patients with chronic active hepatitis B. Other HLA specificities 
showing deviations from control values were not statistically significant after correc-
tion for the number of antigens tested. In conclusion, no evidence was found that the 
elimination of hepatitis B virus is related to HLA phenotype. However, HLA DQwl 
may affect the morphologic type of chronic hepatitis B, since its presence may protect 
against chronic active hepatitis. 
Introduction 
The course of disease after hepatitis B virus (HBV) infection is extremely divergent, 
varying from recovery to the development of chronic active hepatitis, liver cirrhosis 
and death. The course of disease appears not to be related to variation in virulence 
of the HBV itself (l). However, there are many reasons to assume that the course of 
disease after HBV infection is determined by the host's immune system (2,3), as dis-
cussed in chapter II. 
The Major Histocompatibility Complex (MHC) is involved in the regulation of the 
immune response. The class I antigens (HLA-A, -Band -C) are mainly recognized by 
T-cells that have the ability to develop into cytotoxic cells and the class II molecules 
(HLA-DR and -DQ) play a role in the activation of regulatory T lymphocytes (4). 
Several investigations have been performed to detect a relationship between 
HLA and the course of hepatitis B. So far, the results are inconclusive and no statistically 
significant correlation could be found, except in one study (5). The main difficulties 
in the interpretation of the data are the small numbers of patients investigated, the 
inhomogeneity for race and the lack of uniform definition of the liver disease. 
Moreover, no study has been performed which included the presently known HLA 
loci and all possible courses of disease. 
We therefore studied the phenotype frequencies of HLA antigens of class I and 
class II loci in groups of subjects, homogenous for race and with well-defined courses of 
disease after HBV infection. 
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Patients and methods 
Patients. 
Threehundred ninety six subjects were included in the study. They were unrelated, 
Cancasian and of Dutch extraction for two generations. The phenotype frequencies 
ofHLA antigens of 196 subjects with HBV infection were compared with those of 200 
healthy random controls. The patients were eligible for this study on the basis of 
serological signs of current or past hepatitis B, and they were grouped according to 
the courses of their liver disease, defined by standard criteria (6): 1) 47 patients, 
recovered from well documented acute symptomatic hepatitis B, with disappearance of 
HBV antigens and development of antibodies to the hepatitis B surface antigen 
(anti-HBs) and to the hepatitis B core antigen (anti-HBc), 2) 60 subjects, recovered 
from asymptomatic hepatitis B, anti-HBs and/or anti-HBc positive. These subjects 
had had no signs of hepatitis ever before, and were found by routine screenings of 
blood donors; 3) 26 asymptomatic hepatitis B surface antigen (HBsAg) carriers without 
biochemical or histological abnormalities; 4) 16 patients with chronic persistent 
hepatitis B, with transaminases lower than 2x upper limit of normal during more than 
two years and restriction of the inflammatory infiltrate to the portal areas in the liver 
biopsies; 5) 37 patients with chronic active hepatitis B, with transaminases higher 
than 2x upper limit of normal during more than six months and the typical periportal 
piecemeal necrosis in the liver biopsies; 6) 10 patients with continuing chronic 
active hepatitis after elimination of HBV antigens ( anti-HBs, anti-HBc positive). The 
200 controls were randomly selected, healthy blood donors, serologically negative 
for HBsAg and anti-HBc. 
All patients, except those of group 2, had a liver biopsy to establish the diagnosis. 
In patients with chronic hepatitis (groups 4, 5 and 6) at least two biopsies were 
performed with an interval of at least six months. 
Methods. 
HBsAg, anti-HBs and anti-HBc were determined by radioinununoassays (Abbott 
Laboratories, Chicago, ill., USA). Mononuclear cells were isolated from 50 ml of 
heparinized blood by centrifugation on Ficoll-isopaque (Pharmacia, Sweden) (7). 
The cell suspension was washed twice, resuspended in a medium consisting of 25% 
fetal calf serum, 65% RPM! and 10% dimethyl sulfoxyde, and frozen to -80 °C in plastic 
vials. HLA-A, -Band -C typing was performed using the standard Nlli lymphocyte 
microlymphocytotoxicity technique with a set of 120 well-defined sera (8). For HLA-
DR and -DQ typing a panel of 80 platelet-absorbed sera was used in the two-colour 
fluorescence test (9,10,11). 
The phenotype frequencies of 42 HLA determinants of each group were statistically 
compared to those of the control group (12): for each group the Hardy-Weinberg test 
was applied to exclude heterogeneity per locus, and the phenotype frequencies, 
relative risks and their significances were calculated according to Woolf's method 
as modified by Haldane. P-values were corrected for the 42 antigens tested in each 
set of comparisons between one patient group and the control group. 
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TABLE 6.1 HLA ·antigen phenotype frequencies in 196 patients with various courses after hepatitis B 
virus (HBV) infection, compared to 200 healthy controls. 
Group I 2 3 4 5 6 controls 
HLA (47) (60) (26) (16) (37) (10) (200) 
AI 0.298 0.186' 0.423 0.125 0.351 0.500 0.340 
A2 0.681 0.644 0.538 0.625 0.496 0.400 0.525 
A3 0.234 0.254 0.346 0.250 0.189 0.200 0.255 
A9 0.170 0.169 0.192 0.188 0.135 0.200 0.195 
AID 0.043 0.119* 0.077 0.063 0.081 0.000 0.035 
All 0.085 0.119 O.D38 0.125 0.054 0.400* 0.125 
A28 0.106 0.085 O.D38 0.125 0.216* 0.000 0.085 
Awl9 0.213 0.271 0.269 0.250 0.324 0.200 0.230 
B5 0.043 0.034 0.192 0.188 0.108 0.100 0.120 
B7 0.213 0.254 0.269 0.375 0.188 0.100 0.255 
B8 0.234 0.119 0.269 0.188 0.270 0.300 0.225 
Bl2 0.213 0.424 0.346 0.250 0.405 0.400 0.300 
Bl3 0.043 0.017 O.D38 0.125* 0.027 o.ooo 0.030 
Bl4 0.043 0.017 0.038 0.000 0.027 0.000 0.040 
Bl5 0.234 0.186 0.154 0.125 0.243 0.300 0.155 
Bl6 0.021 0.068 0.077 0.063 0.162"' 0.000 0.070 
Bl7 0.128 0.085 0.077 0.063 0.054 0.000 0.100 
BIB 0.087 0.085 0.000 0.063 0.027 0.000 O.D75 
Bw22 0.064 0.119* 0.038 0.063 0.054 0.100 O.D45 
B27 0.106 0.068 0.038 0.063 0.027 0.100 O.D75 
B35 0.319* 0.186 0.154 0.125 0.054 0.100 0.175 
B37 0.043 0.000 O.D38 0.063 0.027 0.200* 0.036 
B40 0.085 0.186 0.077 0.063 0.081 0.100 0.125 
Cwl 0.085 0.017 0.115* 0.125"* 0.027 0.000 O.D35 
Cw2 0.043 0.068 O.D38 0.067 0.027 0.111 0.085 
Cw3 0.319 0.458* 0.154 0.188 0.351 0.556 0.312 
Cw4 0.298 0.220 0.231 0.188 0.108 0.300 0.197 
Cw5 0.085 0.224 0.115 0.063 0.108 0.222 0.154 
Cw6 0.237 0.130 0.211 0.333 0.118 0.250 0.144 
DR! 0.170 0.217 0.154 0.313 0.135 0.100 0.205 
DR2 0.213 0.217 0.308 0.313 0.189 0.200 0.270 
DR3 0.234 0.167 0.346 0.125 0.243 0.400 0.286 
DR4 0.319 0.400* 0.423* 0.125 0.351 0.200 0.245 
DRS 0.319 0.200 0.154 0.500* 0.270 0.100 0.231 
DRw6 0.234 0.350 0.231 0.125 0.162 0.400 0.290 
DR7 0.277 0.133 0.192 0.188 0.324 0.200 0.250 
DRw6 0.108* 0.067 0.000 0.000 0.108* 0.000 O.D25 
DRw9 0.021 0.017 0.077 0.063 O.D28 0.000 0.030 
DRw!O 0.021 0.000 0.000 0.063 0.000 0.200* 0.050 
DQwl 0.574 0.683 0.654 0.750 0.37S- 0.800 0.678 
DQw2 0.363 0.276* 0.538 0.250 0.417 0.500 0.402 
DQw3 0.660* 0.552 0.654 0.688 0.629 0.400 0.447 
., p< 0.05 
*'}.· p ""' 0.001; p corrected for 42 tests = 0.043 
1: recovered from acute symptomatic hepatitis B; 
2: recovered from asymptomatic hepatitis B; 
3: asymptomatic HBV carriers; 
4: chronic persistent hepatitis B; 
5: chronic active hepatitis B; 
6: chronic active hepatitis and HBV elemination. 
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Results 
The groups investigated were homogeneous, since no statistical significant 
heterogeneity per locus was observed by the Hardy-Weinberg test in the six 
groups. 
The phenotype frequencies of the HLA detenninants tested in the groups of subjects 
are listed in table 6.1. Comparison of each group independently with the controls 
showed several statistical deviations at the 5% level for the antigens of the A, B, C 
and D loci. Nearly all of these deviations were not significant after correction. 
However, we found that inpatients with chronic active hepatitis B (group 5), the class 
II antigen DQwl had a significantly lower phenotype frequency than the controls 
(table 6.2). 
In the second instance, we combined groups that shared certain characteristics 
with respect to the two possible effects of the immunological response to HBV infection. 
We joined the groups 1, 2 and 6 (viral elimination), 3, 4 and 5 (no viral elimination), 2 
and 3 (no hepatitis), and 4, 5 and 6 (chronic hepatitis). These larger groups were 
compared to the controls and, for viral elimination and hepatitis, to each other. 
Significant deviations at the 5% level were found for the following antigens (table 
6.3): B5 (low phenotype frequency in 'HBV-elimination'), B35 (high frequency in 
'HBV elimination') and DRw6 (low frequency in 'no HBV elimination'). However, we 
found no statistical deviations after correction for the number of comparisons 
made. 
TABLE 6.2 HLA-DQw 1 in patients with various courses after hepatitis B Virus infection 
group 
I 
2 
3 
4 
5 
6 
all 
controls 
HLA-DQwl 
+ve 
26 
41 . 
17 
12 
14 
8 
!18 
135 
relative 
-ve risk 
21 0.59 
19 1.01 
9 0.88 
4 1.32 
23 0.29 
2 1.62 
78 0.72 
64 
pc : p corrected for 42 antigens tested, compared to controls. 
x' p 
2.70 0.10 
0.00 0.92 
0.10 0.75 
0.26 0.62 
11.45 0.001 
0.50 0.49 
2.49 0.!1 
pc 
ns 
ns 
ns 
ns 
0.043 
ns 
ns 
TABLE 6.3 HLA antigen phenotype frequencies in patients with and without hepatitis B virus 
(HBV) ehmination. 
HLA 
B5 
B35 
DRw6 
HBV 
elimination 
(!17) 
0.043* 
0233* 
0.301 
noHBV 
ehmination 
(79) 
0.152 
0.101 
0.177"* 
·~< : p"' 0.05, compared to the other groups, except that within parentheses. 
controls 
(200) 
0.120 
(0.175) 
0.290 
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Discussion 
The results of HLA studies in hepatitis B have been discongruent and sometimes 
contradictory. No HLA deviations have been described that were statistically 
significant after correction for the number of antigens tested, except one (5). A 
review of a large number of studies was given by Koslow and Shaw in 1981 (13); 
they wrote that these studies provided no conclusive evidence for an association 
between hepatitis B infection, persistent HBsAg carriage or HBsAg positive chronic 
active hepatitis and HLA, because of the divergent patient selections and the number of 
HLA loci and antigens tested. No study had been performed wich included all pos-
sible courses of disease and both HLA class I and class II antigens. In our.study, we 
tried to avoid the problems mentioned above and composed six independent 
groups of subjects with characteristic, well defined courses of disease after HBV 
infection. The subjects were homogeneous for race and they were not related to 
each other. All known HLA loci were typed, including the class II determinants DR 
andDQ. 
Significant numbers of patients have been included into the patient groups to 
provide reliable conclusions about the frequency of the HLA antigens examined, 
with exception of the smaller groups 4 and 6. Comparison of each group with the 
controls showed several deviations at the uncorrected 5% level (table 6.l).The 
phenotype frequency ofB35 was elevated in patients who recovered (group 1), and 
was lowest in the group with chronic active hepatitis B (group 5). A tendency to 
increased frequency of B35 has been described in four studies of HBsAg positive 
chronic hepatitis and in two studies of HBsAg carriers, whereas in one study of 
HBsAg carriers the frequency ofB35 was lower than normal (13). Our results suggest 
that B35 could be weakly associated with the ability to eliminate the hepatitis B virus 
(table 6.3). However, HLA B35 has a low frequency in our general population as well 
as in the patient groups, limiting its pathogenetic importance. 
Elevated frequencies of HLA Al, B8 and DR3 are described in HBsAg negative 
auto-immune chronic active hepatitis (14). In our patients with chronic active 
hepatitis after clearance of the HBV (anti-HBs, anti-HBc positive) (group 6) no devia-
tions of HLA Al, B8 and DR3 were found, although this group is too small to make 
firm conclusions. 
The frequency of class II antigens has hardly been investigated in patients with 
various courses after HBV infection. Lepage et al. (15) studied 25 patients with chronic 
active hepatitis Band found no deviations in DR specificities. Forzani et al. (5) found 
a complete absence ofDR4 in 44ltalian patients with HBsAg positive chronic active 
hepatitis without delta infection. That finding was statistically significant, also after 
correction for the number of tests performed. However, in view of the low frequency 
o!DR4 in the control population (0.185 in the Italian population), the finding of a still 
lower frequency is of ltrnited pathogenetic importance. The increased frequency of 
HLA DR3 described by Forzani et al. (5) was not statistically significant after correction for 
the total number of antigens tested within the patient group. 
In this study we describe a low frequency of DQwl in patients with chronic active 
hepatitis B (group 5) in comparison with the controls. This deviation was statistically 
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significant after correction for the number of antigens tested. Further correction for 
the number of groups tested is in our opinion not applicable, since the six independent 
patient groups represent divergent courses of disease and have in common only the 
fact of previous infection with hepatitis B virus (16). The low frequency ofDQwl was 
charactertstic for group 5, and was not observed in the other patient groups (table 
6.1 ). DQwl is a common HLA determinant in the Dutch population (phenotype 
frequency 0.678). Therefore, a reduction of its phenotype frequency may be of 
pathogenetic importance. 
DQwl belongs to the MHC class II determinants, which are involved in the antigen 
presentation to T -cells ( 4). The proliferative T -cell response has been shown to be 
restrtcted by products of the HLA DR region. Restrtction is the phenomenon that antigen 
sensitized T-cells only recognize the antigen on presenting cells that are sharing a 
HLA class II (-DR or -DQ) determinant. Van Eeden et al. (17) tested a large number of 
distinct monocyte T -cell combinations for their proliferative response to PPD and 
showed that HLA DQwl T-cells were significantly associated with low-responsiveness to 
antigen stimulation. 
Chronic active hepatitis B is characterized by an ongoing attack ofT lymphocytes 
on infected liver cells (18). Simultaneous expression of MHC class II determinants 
and viral antigens on the liver cell surface may play a role in maintaining this attack. 
In this study, DQwl frequency appeared to be significantly lower than normal only in 
the group of chronic active hepatitis B patients. This finding suggests a protective 
role of DQwl against chronic active hepatitis type B and is compatible with the in 
vitro finding of low responsiveness of DQwl T -cells to antigenic stimulation. 
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Starling-points 
This study was designed to find correlations between the various courses of 
disease after hepatitis B virus (HBV) infection and factors that could conceivably 
have influenced the course of disease. 
The aim of the study was to find correlations between parameters of viral replication 
and liver cell damage, factors related to the viral subtypes and the immunological 
response and the various well defined courses of disease after hepatitis B virus 
infection, in order to gain insight into the timing and the mechanism of the development 
of chronic hepatitis B. 
The course of disease after hepatitis B virus infection is heterogeneous (see fig. 
2.3). Acute hepatitis B may cause hepatitis with jaundice, hepatitis without jaundice 
or no hepatitis at all. In any of these instances, the HBV may be cleared, leading to 
recovery, or may persist, resulting in chronic HBV carriership. Chronic HBV carriers 
may have varying degrees of chronic hepatitis, or no hepatitis at all. Viral clearance 
seems to run independently from hepatitis activity, in acute as well as in chronic 
hepatitis B. However, a close relationship between viral replication activity, partial 
viral clearance and hepatitis activity has been described (l-6) in a group of patients 
who have developed chronic active hepatitis, suggesting a causal role of active 
viral replication in the pathogenesis of persisting liver cell degradation. In this 
patient group, serological tests for hepatitis Be antigen (HBeAg) become negative 
during the natural history, which is considered to be a sign of partial viral clearance 
(4). Liver cell damage is often increased during some weeks preceding the seroconver-
sion. After HBeAg seroconversion the virus is usually not completely cleared, but 
incorporated into the host's liver cell genome (7,8).1n the other courses of disease 
such a correlation between viral clearance and liver cell damage has not become 
apparent. In particular, it is not clear whether in early acute hepatitis B liver cell 
damage plays a causal role in viral elimination, or is merely the result of the viral 
infection of liver cells. 
Patients 
The patient groups that were formed in this study had to be distinctive with respect to 
viral elimination and hepatitis activity. 
Viral elimination and liver cell damage were studied simultaneously in patients 
with acute hepatitis B, who had no previous signs of HBV infection, as described in 
chapter Ill. After six months these patients either recovered or became chronic 
HBV carriers. 
Factors related to the viral subtypes and factors related to the immunological 
response, described in the chapters N, V and VI, were studied in the following 
groups of subjects, diagnosed as having: 
- recovered from acute icteric hepatitis B; these patients had effective viral clearance 
together with considerable liver cell damage; 
-recovered from acute non-icteric hepatitis B, with effective viral clearance, but without 
marked liver cell damage; 
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- chronic non-symptomatic HBV carriership, without effective viral clearance and 
without liver cell damage; 
- cl:uconic persistent hepatitis B, without effective viral clearance and with mild non-
progressive liver cell damage; 
- chronic active hepatitis B, without effective viral clearance and with mild to severe 
progressive liver cell damage; 
- chronic active non-viral auto-immune hepatitis, with effective viral clearance and 
mild to severe progressive liver cell damage. 
The patient groups were defined according to standard criteria (9). 
Acute hepatitis B was diagnosed if alanine aminotransferase (ALT) was more than 
2x the upper limit of normal for five days or more; hepatitis B surface antigen 
(HBsAg) and immune globulin M antibody to hepatitis B core antigen (IgM-anti-
HBc) were positive; liver biopsy was in confonnity with acute viral hepatitis without 
signs of chronic hepatitis; no history, symptoms or signs of liver disease had been 
present prior to presentation and no immunosuppressive drugs nor anaesthesia had 
been administered during four weeks prior to the initial symptoms of hepatitis. This 
extensive definition was used to prevent inclusion of patients with an exacerbation 
of pre-existent chronic hepatitis in the acute hepatitis group. 
Recovery from acute icteric hepatitis was defined as normalization of ALI and 
loss of HBsAg in the serum, with development of antibodies to HBsAg (anti-HBs) 
and/ or persistence of lgG-anti-HBc. These patients had previously fulfilled the criteria 
of acute hepatitis B as decribed above. 
Recovery from acute non-icteric hepatitis was defined as normal ALI, negative 
HBsAg in the serum, positive anti-HBs and/oranti-HBc tests and no history, previous 
symptoms or signs of liver disease. These subjects were found by routine screening 
of blood donors. 
Chronic non-symptomatic hepatitis B virus carriers were characterized by a normal 
ALI and positive serum HBsAg during more than six months, no history, symptoms or 
signs of liver disease and a liver biopsy in conformity with asymptomatic HBsAg carriership. 
Patients were only eligible for this group if they had at least one liver biopsy and 
were without signs of hepatitis in all biopsies, to be sure that patients with very mild 
chronic hepatitis would not be included in this group. 
Chronic hepatitis was diagnosed if ALI elevation and positive serum HBsAg 
persisted for more than six months and a second liver biopsy, taken more than six 
months apart from the former, confinned chronic hepatitis, according to the standard 
criteria (9). 
Chronic persistent hepatitis B was defined by the following criteria, in addition to 
those of chronic hepatitis: ALI never higher than 2x the upper limit of normal; serum 
HBsAg positive for more than six months; liver biopsies in conformity with viral 
hepatitis, the mononuclear infiltrate being limited to the portal zones. Some spill-
over of lymphocytes between intact hepatocytes immediately around the portal 
zones was allowed. 
Chronic active hepatitis B was defined by the following criteria, additional to 
those of chronic hepatitis: ALI repeatedly or continuously higher than 2x the upper 
limit of normal; serum HBsAg positive for more than six months; liver biopsies in conformity 
with viral hepatitis and chronic active hepatitis, the mononuclear infiltrate being 
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extended into the liver lobules, with piecemeal necrosis (9). 
Chronic active non-viral auto-immune hepatitis was defined by the following criteria, 
in addition to those of chronic hepatitis: ALI repeatedly or continuously higher than 
2x the upper limit of normal; serum anti-HBs, and/or anti-HBc, anti-nucleic factor 
and liver membrane antibodies positive; liver biopsies in conformity with chronic 
active hepatitis, the mononuclear infiltrate being extended into the lobules, with 
piecemeal necrosis (9). 
The patient groups as defined above were investigated in various paris of this 
study. The number of patients included in different parts of the study varies as a 
result of the availability of the patients to participate to the investigations at different 
times and because of specific additional requirements for particular parts of the 
study, for example, the patients had to be of Caucasian race in the chapters N, V 
and VI. 
All chronic HBV carriers were tested for markers of hepatitis delta virus (HDV) 
infection (10,11). The patients included in this study did not have positive tests for 
delta antigen or antibody to delta antigen. No patients have developed signs of 
acquired immune deficiency syndrome (AIDS) (12) during a follow-up of at least 
three years alter collection of the sera that were investigated in this study. No 
alcoholics and no subjects with impaired cellular immunity, such as renal dialysis 
patients, subjects with Down's syndrome or patients with lymphoma or leukemia 
were included in the study. 
Methods 
Some methods had to be developed to detect HBV related antigens, where no 
standard procedures were available. In particular this was the case in the determi-
nation of the HBsAg titre and the HBeAg PIN ratio (chapter Ill) and the subtyping of 
HBsAg and anti-HBs (chapter IV). The other methods used in this clinical study are 
standard. They are described in the chapters Ill, N, V and VI. Standard statistical 
methods are used in each investigation, with a preference for rank correlation methods 
(13,14) to minimize artefacts caused by non-normally distributed data. 
The studies performed 
Description, results and conclusions 
The first aim of the study was to find correlations between parameters of viral 
replication and liver cell damage alter hepatitis B virus infection, in order to gain 
insight into the timing and the mechanism of the development of chronic 
hepatitis B. 
Parameters of viral replication and liver cell damage were studied in 63 patients 
with acute hepatitis B (chapter Ill). The patients were included in an early stage of 
acute hepatitis B and were followed until recovery odor at least six months. Parameters of 
viral replication (HBV DNA, DNA polymerase, HBeAg and HBsAg) and liver cell damage 
(AIJ, bilirubin) were measured quantitatively or semi-quantitatively in the serum. Viral 
antigens (HBsAg and HBcAg) were determined in liver tissue by immunofluorescence. 
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The data were compared in time, using the point of maximal ALT elevation as the 
reference point. 
After six months 53 patients had recovered and lO had become chronic HBV 
caaters. Two weeks before maximal ALT, patients with different outcome had no 
statistically significant differences in the viral antigens measured. From that time, the 
HBsAg and HBeAg levels fell significantly in patients who eventually recovered and 
remained constantly high in patients who would become chronic HBV caaters. The 
sequence of disappearance from the serum was: HBV DNA and DNA polymerase, 
HBeAg, HBsAg. Viral antigens in liver biopsies were usually only detectable before 
the AIT peak and remained high only in those patients who became chronic carriers. The 
disappearance of HBsAg and HBeAg levels in serum showed no correlation with 
ALT or bilirubin levels in patred data of individual patients. 
This study indicates that the course of disease and especially early clearance of 
the virus is already determined at least two weeks before the maximal ALT. The 
disappearance of viral markers, which reflects a decreased viral replication, occurs 
independently of the timing and the extent of liver cell damage. Decreasing viral 
replication is therefore probably not mediated by necrosis of infected hepatocytes. 
A further conclusion is that quantitative assays of HBsAg and HBeAg appear to be 
early indicators of the prognosis. 
The second aim of the study was to find correlations between factors related to the 
viral subtypes and the various courses of disease after hepatitis B virus infection, in 
order to gain insight into the mechanism of the development of chronic 
hepatitis B. 
The subtype frequencies of HBsAg and anti-HBs as well as risk factors for acquiring a 
HBV infection were compared in a study of 127 patients (chapter IV). Eighty-nine 
patients were chronic HBV carriers with various degrees of hepatitis activity and 38 
had acute hepatitis B with recovery. All subjects were of Caucasian extraction. 
HBsAg was simultaneously present with anti-HBs in 32 of the 89 chronic HBV carriers. 
The HBsAg subtype was ad in 28 and ay in four cases. Anti-HBs could be subtyped 
in 25 cases. Twenty of them had anti-HBs type anti-y in combination with HBsAg 
type ad. In one patient anti-d was found in combination with HBsAg type ay . The 
otherfourpatients had a complex antibody subtype pattern. In the acute hepatitis B 
group, the HBsAg subtype was ay in 25 and ad in 13 cases. Subtype ay was common in 
intravenous drug users, who had mainly acute hepatitis B with recovery, and HBsAg 
subtype ad was predominant in homosexuals, who were matnly chronic HBV carriers. 
Non-drug users had equal chances of acquiring HBsAg subtype ad or ay acute 
hepatitis. However, 7 out of 8 acute hepatitis B patients who developed chronic 
hepatitis B had HBsAg subtype ad. Chronic HBV caaters with simultaneous 
presence of HBsAg and anti-HBs did not have an increased risk of acquiring HBV 
infection compared to chronic HBV carriers without anti-HBs. The frequency of chronic 
HBV caaters with simultaneous HBsAg and anti-HBs correlated with the degree of 
hepatitis activity: three out of 23 (3/23) asymptomatic caaters, 4/20 patients with 
chronic persistent hepatitis B, 20/41 with chronic active hepatitis B and 5/5 with 
chronic active hepatitis and liver cirrhosis. 
These data show that HBsAg and anti-HBs relatively frequently occur together in 
chronic HBV caaters and that the frequency of co-occurrence increases with the 
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severity ofHBV related liver disease. The detectable anti-HBs subtypes were always 
reactive to HBsAg subtypes other than the HBsAg subtypes present in the sera. 
These findings, as well as reports of a similar pattern of HBsAg-specific circulating 
immune complexes (15,16) and non-specific antibody formation after influenza 
vaccination (17) in chronic HBV carriers suggest that the non-specific anti-HBs 
formation may be part of a qualitative defect in the immune response to HBV 
antigens in such patients. The hypothesis that co-occurrence of HBsAg and anti-
HBs is caused by two consecutive infections with HBV of different subtypes is not 
supported by the equal distribution of risk factors for HBV infection that was found in 
chronic HBV carriers groups with and without anti-HBs. There is still some doubt 
whether HBV subtypes ad and ay have the same pathogenetic properties in view of 
the higher incidence of subtype ad in chronic hepatitis despite an equal incidence 
of ad and ay in acute hepatitis in non-drug users. 
The third aim of the study was to find correlations between the immune response 
and the various courses of disease after hepatitis B virus infection. The parts of the 
study that are related to this question are described in chapters V and VI. 
In chapter V the determination of immunoregulatory T-cell subsets in the 
peripheral blood of97 patients with various courses after HBV infection is discussed. 
Twenty three of the patients were asymptomatic HBV carriers, 13 had chronic 
persistent hepatitis B, 19 had chronic active hepatitis B, 7 had chronic active 
hepatitis with anti-HBs or anti-HBc, and 35 had recovered from acute hepatitis B 
with development of anti-HBs. Peripheral blood mononuclear cells were specifically 
labeled with monoclonal Leu-! (reactive to T-cells), Leu-2a (reactive to T 
suppressor and cytotoxic cells), Leu-3a (reactive toT helper cells) antibodies and 
analyzed by flow cytometry. The T-cell subset counts of the combined groups of 
patients who had cleared the virus were compared to those of the combined patient 
groups with persistence of the virus. With respect to liver cell damage, the patient 
groups were compared separately. 
No statistical differences were found between patients with and without 
clearance of the virus. Comparison of the patient groups separately showed a 
significant reduction of Leu-2a positive cells (p < 0.05) in patients with chronic 
active hepatitis B compared with healthy subjects who had recovered from hepatitis 
B. Chronic active hepatitis B patients of the subgroup with anti-HBe exhibited a 
more pronounced reduction in Leu-2a positive cells (p < 0.02), whereas the 
concentration of these cells was normal in the subgroup withHBeAg. The patients in 
the other HBV positive groups with anti-HBe had normal T-cell subset concentrations. 
The number of Leu-2a positive cells in the seven patients with chronic hepatitis after 
virus elimination was as low as that found for the chronic active hepatitis B group 
(0.05 < p < 0.10 in comparison with healthy controls). 
These findings suggest that elimination of HBV is unlikely to be related to the 
relative number of peripheral T -cell subsets, and that viral persistence is not caused 
by a general defect in the host's immune response. With the methods used, a HBV 
related antigen specific immunologic defect cannot be excluded. However, 
persistence of active inflammation of the liver after partial or total clearance of the 
virus might be mediated by a high T helper/T suppress.or cell ratio, which may be an 
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expression of enhanced immunoreactivity against hepatocytes rather than against 
viral antigens in these patients. 
Genetic factors possibly influencing the course of disease after HBV infection are 
discussed in chapter VI. The phenotype frequency of HLA antigens was studied in 
396 unrelated subjects of Dutch, Caucasian extraction. Six groups of individuals 
with various courses after HBV infection were compared to healthy controls. The 
hepatitis B patients were grouped according to the criteria formulated above: l) 4 7 
had recovered from acute symptomatic hepatitis B, 2) 60 subjects, recovered from 
asymptomatic hepatitis B, 3) 26 asymptomatic HBV carriers without biochemical or 
histological abnormalities 4) 16 patients with chronic persistent hepatitis B, 5) 37 
patients with chronic active hepatitis B, 6) 10 patients with continuing chronic active 
hepatitis after elimination of HBV antigens (anti-HBs, anti-HBc positive). The 200 
controls were randomly selected healthy blood donors, serologically negative for 
HBsAg and anti-HBc. All patients, except those of group 2, had a liver biopsy to 
establish the diagnosis. 29 class I and 13 class II HLA antigens were assayed by 
standard rnicrolymphocytotoxicity tests. 
Comparison of each group independently with the controls showed several 
statistical deviations at the 5% levelfor antigens of all HLA loci. Nearly all deviations 
were not significant after correction for the number of tests performed. However, we 
found that in patients with chronic active hepatitis B (group 5), the class II antigen 
DQwl had a significantly lower phenotype frequency than in the controls. 
Combination of patient groups with and without viral elimination as well as groups 
with and without hepatitis activity ytelded no additional HLA deviations that were 
statistically significant after correction. 
In conclusion, evidence was found that the class II HLA antigen DQw l may 
protect against chronic active hepatitis. The reduction of HLA DQw l may be of 
pathogenetic importance because it is a common HLA determinant in the Dutch 
population. The MHC class II determinants are involved in the antigen presentation 
to T-cells (18). HLA DQwl T-cells have shown to be associated with low-
responsiveness to antigen stimulation (19). Simultaneous expression ofMHC class II 
determinants and viral antigens on the liver cell surface may play a role in 
maintaining the ongoing attack ofT lymphocytes on infected liver cells in chronic 
active hepatitis B. The finding of a low DQwl frequency only in the group of chronic 
active hepatitis B patients suggests a protective role ofDQwl against chronic active 
hepatitis type B and is compatible with the in vitro finding of low responsiveness of 
DQwl T-cells to antigenic stimulation. No evidence was found that the elimination of 
HBV is related to HLA phenotype. 
General discussion 
The results of this study suggest that different immunological mechanisms are 
involved in the clearance of the HBV and the development of liver cell damage at 
different stages in the courses of disease after HBV infection. 
In the early acute disease the clearance of the HBV seemed to precede liver cell 
damage in patients who recovered. The precise cause of the defective early viral 
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elimination in patients who developed chronic hepatitis remains unclear. Factors 
related to this problem were investigated in the other parts of this study. A slight 
preference of HBV with HBsAg subtype ad to coincide with chronic hepatitis B was 
observed in Dutch patients with chronic hepatitis B and in patients with acute 
hepatitis B who eventually became chronic HBV carriers. Therefore, some influence 
of the viral HBsAg subtype on the course of disease cannot be excluded. 
Simultaneous presence of HBsAg and non-specific anti-HBs was found relatively 
frequently in chronic HBV carriers with more severe liver damage. It was found only 
in three patients with acute hepatitis B. Two of them eventually became chronic HBV 
carriers. Nevertheless the co-occurrence phenomenon, suggesting em immunologic 
defect resulting in production of less-specific humoral factors, seems to be 
correlated closer to liver cell damage than to HBV clearance as such. No indication 
of a general defect in the immune response of the host was found by investigation of 
immunoregulatory T -cell subsets in patients who did not clear the virus. A genetic 
basis for persistence or clearance of the HBV was not found by detection of HLA 
antigens in relatively large groups of subjects. 
Insufficient clearance of the virus is a common feature of chronic HBV carriers at 
first sight. However, the degree of viral clearance may be different in the various 
courses of chronic HBV carriership and in individual patients during different stages 
of their course of disease, as discussed in chapter II, section 2.4. For that reason, the 
chronic HBV carriers included in this study had carefully and clearly defined 
courses of disease. HBsAg subtypes, non-specific anti-HBs formation, immuno-
regulatory T-cell subsets and HLA phenotype frequencies, however, did not 
correlate with the degree of viral clearance in these patients. 
Liver cell damage in the early stage of acute hepatitis B did not correlate in time 
or severity with the decreasing quantitative parameters of viral replication in cases 
that eventually recovered. This is of importance with respect to the two main 
mechanisms of viral clearance that have been proposed. The first hypothesis states 
that elimination of the HBV is achieved by destruction of all infected liver cells (20). 
The second hypothesis postulates suppression of viral protein synthesis by antiviral 
antibodies (21 ). The results of this study support the proposed mechanism of 
selective suppression of viral protein without destruction of all infected liver 
cells. 
Factors related to liver damage in chronic HBV carriers were investigated in the 
other parts of this study. Non-specific anti-HBs was observed relatively frequently in 
chronic HBV carriers with more advanced liver damage. This kind of patients also 
produced aspecific antibodies after Influenza vaccination. Therefore, these 
observations are interpreted as being a sign of a qualitative defect of the host's 
immune response rather than being related merely to the viral subtypes. A low 
number ofT suppressor cells was found in patients with ongoing chronic active 
hepatitis after partial or complete clearance of the virus. This would be consistent 
with immunoreactivity against liver cell constituents, without the immunostimulating 
effects of expression of viral antigens on the liver cell surface in such patients. 
Genetic factors were found to be possibly involved in the regulation of cytotoxicity 
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against hepatocytes. The HLA DQw l phenotype frequency was significantly low in 
the patient group with chronic active hepatitis, which is in concordance with the fin-
ding in vitro that DQw l lymphocytes are low-reactive to antigenic stimulation 
(19). 
Other factors that cause damage to the liver or interfere with the host's immune 
system, may influence the course of disease after HBV infection. The cytotoxic 
hepatitis delta virus, which replicates only in hosts who are HBV positive, decreases 
the HBV DNA synthesis and may cause variable degrees of liver damage, additive 
with that caused by HBV (1 0). The chronic HBV patients included in this study did 
not have positive tests for delta antigen or antibody to delta antigen. A high 
prevalence of chronic HBV earners is found in subjects with impaired cellular immunity, 
such as renal dialysis patients, subjects with Down's syndrome and patients with 
lymphoma or leukemia (22,23) and in AIDS patients (12). Such patients were not 
included in the study. 
The results of this study allow some additional remarks about the therapeutic 
approach of hepatitis B, which is an important end-goal of many investigations in 
this field. 
ln acute hepatitis B the decisive course seems to be set at least two weeks before 
m=imal ALT. At this time no differences in quantitative viral parameters were 
observed between patients who would recover and those who would become chronic 
HBV carriers. Early antiviral therapy theoretically might be effective in preventing 
chronic HBV carriership in the latter category of patients. These patients with a 
potentially chronic course could possibly be selected for therapy at an early stage 
by repeated quantitative HBsAg or HBeAg assays, which appeared to be early and 
sensitive parameters of viral clearance in acute hepatitis B. 
ln chronic hepatitis B, immunosuppressive therapy has been shown to be only 
partially effective by decreasing the hepatitis activity (24,25), probably because the 
continuing viral antigen expression seems to play a major role in the cytotoxic 
activity (26).ln fact, this kind of therapy showed detrimental effects on the prognosis 
of patients treated that way. Therefore, immunosuppressive therapy is no longer 
given to chronic hepatitis B patients.ln this study a subgroup of patients with chronic 
active hepatitis B who continued to have high hepatitis activity after HBeAg 
seroconversion was discemable from other chronic HBV carriers because of a low 
number of T suppressor cells. This finding would be consistent with enhanced 
immunoreactivity against liver cell membrane antigens rather than viral antigens, 
corresponding to the supposed cytotoxic mechanism in chronic active non-viral 
hepatitis (27,28). The latter disease responds well to irnmunosupressive therapy 
(28). Therefore, immunosuppressive therapy theoretically might be effective in the 
HBeAg negative subgroup of patients with chronic active hepatitis B. 
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Aim of the study 
The aim of this study is formulated in chapter I: "To find correlations between l) the 
various courses of disease after infection with the hepa!ilis B virus and 2) quantitative para-
meters of viral replication and liver cell degradation, viral subtypes and the irrununological 
response, in order to obtain more insight into the timing and the mechanisms of the 
development of chronic hepatitis B". 
Motivcrlion 
The main motivation for this study was the lack of proven effective therapy for 
patients who have developed chronic hepatitis B. The theoretical basis for designing a 
treaiment is incomplete. The key factors that determine the development into chronic 
hepatitis B are unknown, as well as the point of time at wich these factors play their 
decisive role in the course of disease. 
All parts of this study deal with the spectrum of various, well defined, courses of 
disease wich may develop after infection with the hepatitis B virus (HBV). The acute 
infection usually results in complete recovery with clearance of the virus. Defective 
clearance of the virus leads to chronic HBV carrtership. Both in acute infection and 
chronic carriership the degree of hepatitis may vary from severe to completely 
absent, indicating a discrepancy between viral elimination and liver cell destruction. 
Therefore, the immunological mechanisms regulating viral elimination and liver cell 
destruction may be, at least partially, different. 
Design 
This study was designed to get more information on some aspects that are related 
to the timing and the mechanism of the development of the wide range of courses of 
disease after infection with just one type of vtrus. The following questions were put 
forward: at what time during the acute desease is the course directed to chronicity?; 
are early changes in viral replication, viral elimination or liver cell degradation 
indicative for the change of course to chronicity?; are viral subtypes or antibodies 
directed against viral subtypes related to the development of a particular clinical 
course?; are irnmunoregulatory peripheral T -cell subsets correlated with the various 
clinical courses after HBV infection?; is there a genetic basis which predisposes to 
effective or defective viral clearance, tolerance of chronic viral presence without 
hepatitis, or intolerance with chronic active hepatitis? 
Patients 
The patient groups consisted of: patients with acute hepatitis B, subjects who had 
recovered from acute icteric hepatitis B, subjects who had recovered from acute 
non-icteric hepatitis B, chronic HBV carriers without hepatitis, chronic HBV carriers with 
chronic persistent hepatitis, chronic HBV carriers with chronic active hepatitis and 
patients who had cleared the HBV and had developed chronic active auto-immune 
hepatitis. 
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Hepatitis B virus infection. a review 
A review of the literature concerning HBV infection is given in chapter II. Topics 
which me related to the atms of this study and the methods that me used me 
emphasized. 
The HBV is a DNA containing virus. It mainly replicates in human liver cells. The 
coat protein contains the hepatitis B surface antigen (HBsAg). The viral core 
contains the DNA and the hepatitis B core antigen (HBcAg) and hepatitis B e 
antigen (HBeAg) (see fig 2.1). The main viral subtypes me expressed in the HBsAg 
types ad and ay, having determinant a in common. The small DNA molecule is 
partly double-stranded. The incomplete strand is repaired by DNA polymerase 
using the complete strand as a template. The complete strand contains lmge open 
reading frames, coding for HBsAg, DNA polymerase and polypeptides containing 
HBcAg and HBeAg, (see fig 2.2). The HBVDNA can occur in the liver cells either in a 
freely replicating form or integrated in the liver cell genome. Integrated HBV DNA is 
mostly found in the liver cells of HBeAg negative HBsAg positive chronic HBV 
carriers and in hepatocellulm cmcinoma cells. 
HBV products detected in serum and liver can be used as mmkers after the 
clinical stage after HBV infection. Qualitative HBsAg and HBeAg detection is 
widely used, in contrast to quantitative determination of these antigens. HBsAg, 
HBcAg and HBeAg localizations in liver tissue me demonstrated with immuno-
fluorescence and immunoperoxydase techniques. The viral antigen expression in 
liver tissue is believed to be inversely related to the clemance of the virus. DNA 
polymerase activity is a mmker of the presence of DNA containing HBV pmticles. 
HBV DNA in serum and liver is detected by moleculm hybridization techniques. 
DNA polymerase activity and HBV DNA both point to active viral replication. 
The spectrum of clinical courses after HBV infection has already been 
summarized at the beginning of this chapter, stressing the discrepancies between 
viral clemance and hepatitis activity. However, the natural history of chronic active 
hepatitis B shows a close inverse relationship between pmtial viral clemance and 
hepatitis activity in cases that have reached the stage of HBeAg seroconversion. 
This observation suggests a causal role of active viral replication in the 
pathogenesis of persisting liver cell degeneration. Therapeutic intervention of 
chronic hepatitis B by means of immunosuppressive or immunostimulatory me-
thods has not been proven to be effective. A temporary suppression of viral 
replication can be achieved by antiviral therapy. 
The mechanisms of liver cell degeneration and viral elimination, both seeming to 
be immunological by nature, me not identical, as mentioned above. Liver cell 
degeneration is likely to be mediated by the cellulm immune system. No close 
relationship of humoral immunologic factors and liver cell necrosis has become 
appment. According to the classical theory, the cell-mediated immunity may 
account for liver cell necrosis by T -cell cytotoxicity, evoked by the expression of 
HBV-associated antigens on the liver cell surface. This mechanism requires dual 
recognition of viral and self (HLA-) antigens on the liver cell membrane. Chronic 
hepatitis B would then be the result of insufficient viral clemance and continuing 
expression of viral antigens on the cell surface. Other theories stress the role of 
changes in liver cell membranes or immunoregulatory substances in the development to 
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chronicity. Many studies have been performed with respect to these questions, in 
particular on the function of the general cellular immune system, cytotoxic 
lymphocytes and suppressor cells, but no homogeneous results have emerged and 
no significant correlotion with hepotitis B disease activity has been found. 
Viral elirninotion may be mediated by the cellular as well as by the humoral 
immune system. Humoral immunity probably plays an important role in the initial 
viral clearance in acute hepotitis B. Antiviral antibodies are also known to suppress 
viral replicotion in some other viruses than the HBV. One hypothesis assumes that 
this mechanism is also applicable to HBV infection and that antiviral antibodies 
may suppress the synthesis of HBV proteins. According to this hypothesis, the infected 
liver cells do not need to be destroyed to clear the virus.ln contrast, another main 
hypothesis postulates that HBV eliminotion is the result of destruction of all infected 
liver cells. 
The investigo:tions perfor:med 
Chapter Ill deals with the questions concerning the time at which the course of 
disease during acute hepotitis B is directed to chronicity and whether early changes 
in viral replicotion, viral eliminotion or liver cell damage are indicotive for the 
change of course to chronicity. 
The disappearance of viral antigens in relation to liver cell destruction was studied in 
63 potients with acute hepotitis B. Hepotitis B virus DNA, DNA polymerase activity, 
HBeAg and HBsAg were measured quantitotively in serum, and viral antigens were 
determined in liver biopsies by immunofluorescence. All data were related in time to 
the alanine aminotransferase (ALI) peak as a marker of maximum liver cell destruction 
Six months after initial symptoms 53 potients had recovered and lO had become 
chronic HBsAg carriers. At the onset of disease no differences in viral antigens were 
observed between the two groups with different outcome. In potients who 
recovered, the HBsAg and the HBeAg levels decreased significantly from two weeks 
prior to the ALT peak onwards. The disappearance of HBeAg and HBsAg occurred 
independently of the extent of the liver disease. HBV DNA, DNA polymerase and 
viral antigens in liver biopsies were mainly detectable before and around the ALT 
peak. In potients who developed chronic hepotitis, viral antigens in the serum and 
liver tissue remained consistently high. 
These findings indicate that the final course of the acute hepotitis B is set at least 
two weeks before the maximum hepotitis activity and that quantitotive assays of 
HBsAg or HBeAg appear to be early indicators of prognosis. The disappearance of 
viral markers, prior to and independently of the extent of liver cell necrosis, suggests 
that suppression of the viral protein synthesis is an additional mechanism of virus 
elirninotion, apart from destruction of infected liver cells. 
In chapter N the relotionship between viral sulotypes or antibodies against viral 
sulotypes and the development of a particular clinical course is discussed, as well as 
some aspects of humoral immunity. 
Simultaneous presence of HBsAg and anti-HBs was detected in 32 out of 89 
Dutch chronic HBV carriers of Caucasian race. The sulotype frequencies and the 
distribution of risk factors for acquiring a HBV infection were compared in the chronic 
82 
chaptervm 
HBV carriers and 38 patients with acute hepatitis B who recovered. In the chronic 
HBV carriers, HBsAg was subtyped ad in 28 and cry in four cases. Anti-HBs could be 
subtyped in 25 cases using reference antigens discriminating between d, y, and 
w l-w4 determinants. In 20 out of these 25 patients HBsAg subtype ad (HBsAg/ad) 
was accompanied by antibody to determinant y (anti-y), whereas HBsAg/ay and 
anti-d were simultaneously detected in the serum of one patient. The antibody 
patiem in sera from the remaining patients was complex. In the acute hepatitis B 
group, HBsAg was subtyped cry in 25 and ad in 13 cases. Thus, in our patients a 
predominance of cry was found in acute hepatitis with recovery and ad in chronic 
HBV carriers. This difference is par'Jy caused by the prevalence of cry in drug-users 
and ad in homosexuals. Non-drug users appeared to have an equal chance to 
acquire HBsAg/ ad or HBsAg/ cry acute hepatitis. 
Eighteen anti-HBs positive chronic HBV carriers were matched for age, histology, 
and HBeAg status with 18 anti-HBs negative chronic HBV carriers. No differences in 
risk factors for acquiring a hepatitis B infection were found. These results do not 
support the hypothesis that co-occurrence of HBsAg and anti-HBs is due to two 
consecutive infections with hepatitis B virus. The frequency of the co-occurrence of 
HBsAg and anti-HBs was found to be related to the degree of progressive liver 
disease, since anti-HBs was found in three out of 23 asymptomatic HBV carriers, in 
four out of 20 chronic persistent hepatitis B patients, in 20 out of 41 chronic active 
hepatitis B patients, and in all five patients with chronic active hepatitis B and 
cirrhosis. The high frequency of anti-HBs in patients with advanced liver disease 
may be the result of a disturbed immunologic response mechanism. 
In chapter V the investigations on peripheral T -cell subsets in the various clinical 
courses after HBV infection are discussed. 
The course of disease after a HBV infection is probably determined by the cellular 
immune response after the host, which is par'Jy regulated by the T helper and T 
suppressor cells. Immunoregulatory T-cell subsets were counted in the peripheral 
blood of 97 patients with various courses after HBV infection: 23 of these patients 
were asymptomatic HBsAg carriers without detectable liver disease, 13 had chronic 
persistent hepatitis B, 19 had chronic active hepatitis B (ll HBeAg, 8 anti-HBe), 7 
had chronic active hepatitis with anti-HBs, and 35 were healthy controls with anti-
HBs after recovery from acute hepatitis B. Peripheral blood mononuclear cells were 
specifically labeled with monoclonal Leu-! (T-cells), Leu-2a (T suppressor/ 
cytotoxic cells), and Leu-3a (T helper cells) antibodies and analyzed by flow 
cytometry. 
Leu-3a/Leu-2a ratios for patients with persistence of the virus infection did not 
differ from those found for patients who cleared the HBV antigens. These findings 
suggest that elimination of HBV as such is unlikely to be related to the relative 
number of peripheral T-cell subsets. However, evidence was found that the number 
of T suppressor cells had decreased in the subgroup of patients with ongoing 
chronic active hepatitis and anti-HBe. This subgroup of patients who develop 
chronic active hepatitis after partial clearance of the virus probably have an 
enhanced immunoreactivity compared with those running the commoner courses of 
this disease. 
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Chapter VI concerns the genetic basis which may predispose to a particular 
course of disease after HBV infection. 
In order to find a possible relationship between the course of disease and the 
phenotype frequency of HLA determinants, 396 Dutch subjects of Caucasian race 
were studied. Six groups of individuals with various courses after HBV infection were 
compared to healthy controls. The hepatitis B patients were grouped according to 
standard criteria: 1) 4 7 had recovered from acute symptomatic hepatitis B, 2) 60 
had recovered from asymptomatic hepatitis B, 3) 26 were asymptomatic HBV 
carriers, 4) 16 had chronic persistent hepatitis B, 5) 37 had chronic active hepatitis B 
and 6) 10 had chronic active hepatitis after elimination of hepatitis B antigens. 29 Class I 
and 13 Class II HLA-antigens were assayed by standard microlymphocytotoxicity 
tests. 
The phenotype frequency of the Class II antigen DQwl appeared to be 
significantly lower in patients with chronic active hepatitis B. Other HLA specificities 
showing deviations from control values were not statistically significant after 
correction for the number of antigens tested. In conclusion, no evidence was found 
that the elimination of HBV is related to HLA phenotype. However, HLA DQwl may 
affect the morphologic type of chronic hepatitis B, since its presence may protect 
against chronic active hepatitis. 
A general description and discussion of the study is given in chapter VII. The 
starting-points, patient selection and methods, as well as the studies performed are 
discussed in view of the aims of the study. 
Conclusions 
The main results of the study indicate that different immunologic mechanisms are 
involved in the clearance of the HBV and the development of liver cell necrosis at 
different time-points in the various courses after HBV infection. The conclusions can 
be grouped with respect to HBV elimination and liver cell degeneration in acute 
and chronic hepatitis B. 
The HBV clearance in early acute hepatitis B seems to precede maximal liver cell 
necrosis by at least two weeks in cases of recovery. No signs of HBV clearance have 
become apparent during early acute hepatitis B in cases that eventually became 
chronic HBV carriers, indicating that the course of disease is set before clinical 
symptoms became apparent. HBsAg subtype ad may be slightly related to deficient 
HBV clearance in the group of Dutch patients studied. 
Liver cell damage in early acute hepatitis B shows no correlation in time or extent 
with HBV clearance, supporting the hypothesis that viral clearance may (partially) 
be achieved by suppression of virus production without destroying liver cells. Non-
specific anti-HBs was found to occur more frequently in patients with advanced 
stages of HBV-related liver disease and seems to be closer correlated to liver 
damage than to HBV clearance. It is interpreted to be a sign of a qualitative defect 
in the immune response to HBV infection. The decreased number ofT suppressor 
cells found in patients with ongoing chronic active hepatitis B after HBeAg 
seroconversion may be an indication of enhanced immuno-reactivity in these 
patients. The low phenotype frequency of HLA DQw 1 in the patient group with chronic 
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active hepatitis B shows that genetic factors are possibly involved in the regulation 
of hepatitis activity. 
The findings reported in this thesis have possible implications for the treatment of 
hepatitis B. Antiviral drugs may be more effective if given early in the course of 
disease. Repeated quantitative assays of HBsAg and HBeAg may be useful in the 
identification of patients with a potentially chronic course. A subset of chronic 
hepatitis B patients, without HBeAg, have some hallmarks of "autoimmune" hepatitis, 
and these patients may possibly benefit from immunosuppression. 
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SAMENVATTING EN CONCLUSIES 
hoofdstuk. VIII 
Doel van het onderzoek 
In hoofdstuk I is het doe! van dit onderzoek als volgt geformuleerd: ''het vinden 
van correlaties tussen I) de verschillende beloopsvormen van hepatitis B en 2) 
kwantitatieve parameters betreffende virale replicatie en levercelverval, subtypen 
van het hepatitis B virus en de immunologische respons, ten einde beter inzicht te 
verkrijgen in het tijdstip waarop en het mechanisme waardoor chronische hepatitis 
B ontstaat". 
Aanleiding 
De belangrijkste aanleiding voor dit onderzoekis het ontbreken van een blijvend 
werkzame behandeling van chronische hepatitis B. De theoretische basis voor een 
dergelijke therapie is nog incompleet. De reden waarom hepatitis B bij bepaalde 
patienten chronisch wordt is niet bekend, evenmin als het tijdstip waarop dit 
gebeurt. 
In dit onderzoek komen telkens de verschillende beloopsvormen ter sprake die 
zichkunnen voordoen na besmetting met het hepatitis B virus (HBV). Acute hepatitis 
B geneest meestal, en hierbij word! het virus opgeruimd. Indien het virus niet voile-
dig word! geelimineerd dan ontstaat chronisch hepatitis B dragerschap. De mate 
van hepatitis kan zowel bij de acute hepatitis B als bij chronisch dragerschap aan-
zienlijk varieren, zodat er geen duidelijk verband lijktte bestaan tussen de mate van 
levercelbeschadiging en eliminatie van het virus. Mogelijk zijn daarom verschil-
lende (immunologische) mechanismen verantwoordelijk voor levercelbeschadi-
ging en viruseliminatie. 
Opzet van het onderzoek 
Dit onderzoek werd zo opgezet dat aspect en betreffende het tijdstip waarop en 
het mechanisme waardoor chronische hepatitis B ontstaat konden worden onder-
zocht. Hierbij werden de volgende vragen geformuleerd: op welk tijdstip word! 
gedurende de acute lase van de ziekte het beloop in chronische richting gestuurd?; 
geven vroege veranderingen in virale replicatie, virale eliminatie of levercel 
beschadiging gedurende de acute lase aanwijzingen voor een a! dan niet chro-
nisch beloop ?; hebben virale subtypen of antistoffen tegen subtypen een correlatie 
met de ontwikl::eling van een bepaald ziektebeloop ?; is erverband tussen het voor-
komen van bepaalde soorten T-cellen in het bloed en de verschillende beloopsvor-
men van hepatitis B ?; is er een genetische basis die voert tot voldoende of 
onvoldoende opruiming van het virus, het laatste in combinatie met tolerantie van 
het virus bij chronisch HBV-dragerschap zonder hepatitis, of met intolerantie van 
het virus bij chronische hepatitis B. 
Patienten 
De patienten-groepen werden als volgt samengesteld: patienten met acute 
hepatitis B, personen die genazen na acute icterische hepatitis B, personen die 
genazen na acute aniclerische hepatitis B, chronische HBV dragers zonder hepatitis, 
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chonische HBV dragers met chronisch persisterende hepatitis, chronische HBV dra-
gers met chronisch actieve hepatitis en patienten die het HBV hebben opgeruimd 
maar chronisch actieve auto-irnmuun hepatitis hebben ontwikkeld. 
Hepatitis B, een overzicht 
In hoofdstuk II wordt een overzicht gegeven van de literatuur belreffende hepatitis B. 
De nadruk wordt gelegd op onderwerpen die belrekking hebben op het doe! van 
dit onderzoek en de gebruikte methoden. 
Het HBV is een DNA-virus. Het verrnenigvuldigt zich voomamelijk in menselijke 
levercellen. Het manteleiwit bevat het hepatitis B oppervlakte (surface) antigeen 
(HBsAg). In de viruskem (core) bevindt zich het DNA, het hepatitis B core antigeen 
(HBcAg) en het hepatitis Be antigeen (HBeAg) (zie fig. 2.1 ). De belangrijkste HBsAg 
subtypen zijn ad en ay. Zij hebben detenninant a gemeenschappelijk. Het l::leine 
DNA-molecuul is circulair en bestaat gedeeltelijk uit twee strengen. Met behulp van 
DNA-polymerase wordt de incomplete streng verder opgebouwd. De complete 
streng bevat de genetische code voor HBsAg, DNA-polymerase en polypeptiden 
die HBcAg en HBeAg bevatien (zie fig. 2.2). HetHBV-DNAkan in de levercellenzowel 
in vrije vonn als geintegreerd in het gastheer-genoom voorkomen. In de vrije vorrn 
kan het virus zich repliceren. Geintegreerd HBV-DNA komt voomamelijk voor in 
levercellen van HBeAg-negatieve HBsAg-positieve chronische HBV-dragers, 
nadat het virus (-genoom) gedeeltelijk is opgeruimd, en in cellen van hepatocellu-
lair carcinoom. 
Het aantonen van bestanddelen van het HBV in serum en lever kan worden ge-
bruikt ter indicatie van de fase waarin het beloop van de hepatitis B zich bevindt. 
HBsAg en HBeAg in serum worden, gewoonlijk kwalitatief en bij uitzondering kwan-
titatief, bepaald met radio-immune-assays of enzyme-immune-assays. HBsAg, 
HBcAg en HBeAg worden in leverweefsel aangetoond met immunofluorescentie-en 
immunoperoxydase-technieken. DNA-polymerase-activiteit wordt gemeten met 
behulp van incorporatie van radio-actief thymidine. HBV-DNA kan in serum en 
lever worden aangetoond met behulp van moleculatre hybridisatie. Zowel DNA-
polymerase-activiteit als aantoonbaar HBV-DNA zijn een uiting van actieve 
virale replicatie. 
In het natuurlijke beloop van hepatitis B kan de mate van hepatitis zowel bij de 
acute hepatitis B als bij chronisch dragerschap aanzienlijk varieren, zodat er geen 
eenduidig verb and lijkt te bestaan tussen de mate van levercelbeschadiging en eli-
minatie van het virus. Het natuurlijke beloop van chronisch actieve hepatitis B na 
verdwijnen van HBeAg, meestal gepaard gaande met verrnindering van de mate 
van hepatitis, vertoont echter een omgekeerd verband tussen (gedeeltelijke) elimi-
natie van het virus en de levercelbeschadiging. In dit geval speelt actieve virale 
replicatie mogelijk een causale rol in de pathogenese van persisterende levercelbe-
schadiging. 
Therapeutische interventie van chronische hepatitis B rniddels immunosuppres-
siva of irnmunostimulantia is niet effectief gebleken. Met antivirale therapie kan tij-
delijke suppressie van de virale replicatie worden verkregen. 
De mechanismen van levercelbeschadiging en viruseliminatie zijn waarschijnlijk 
niet identiek. Bij levercelbeschadiging speelt de cellulatre irnmuniteit de belangrijkste 
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rol. Humorale factoren zijn hierbij nietvan invloed gebleken. Het cellulaire immuun-
systeem kan levercelnecrose veroorzaken door middel van T-ee! cytotoxiciteit 
Hi.ervoor is gelijktijdige herkenning van virale en HLA-antigenen op het levercelop-
pervlak noodzakelijk. Volgens de klassieke theorie is chronische hepatitis B het 
gevolg van onvoldoende virale eliminatie en voortgaande expressie van virale 
antigenen op het leverceloppervlak. Andere theorieen met betrekking tot de ont-
wikkeling van chronische hepatitis B benadrukken de rol van veranderingen in de 
levercelmembraan of van stoffen die het irnmuunsysteem beinvloeden. Onder-
zoekingen betreffende de activiteit vanhet cellulaire immuunsysteem hebben voor-
alsnog geen homogeen resultaat opgeleverd. 
In het mechanisme van viruseliminatie zijn waarschijnlijk zowel de cellulaire als 
de humorale immuniteit van belang. Antilichamen hebben een belangrijke lunette 
bij de opruirning van het virus kart na infectie. Bij andere virussen is gebleken dat 
antistoffen de productie van virale eiwitten kunnen remmen. Een hypothese stelt dat 
dit mechanisme ook voor het HBV kan gelden. Volgens deze hypothese behoeven 
geinfecteerde levercellen niet te worden vernietigd om het HBV te elimineren. Dit is 
in tegenstelling met de meest gangbare hypothese, waarin HBV eliminatie het 
gevolg is van destructie van aile geinfecteerde levercellen. 
Het verrichte onderzoek 
In hoofdstuk ill word! het onderzoekbeschreven naar het tijdstip waarop het ziek-
tebeloop tijdens de acute lase van hepatitis Bin chronische richting word! gestuurd 
en naar vroege veranderingen in virale replicatie, virale elirninatie of levercel 
beschadiging die gedurende de acute lase aanwijzingen voor een a! dan niet chro-
nisch beloop kunnen vormen. 
Bij 63 patienten met acute hepatitis B werd het verdwijnen van virusantigenen in 
verhouding tot de mate van levercelbeschadiging bestudeerd. HBV-DNA. DNA-
polymerase-activiteit, HBeAg en HBsAg werden kwantitatief in het serum bepaald. 
De virale antigenen werden in leverbiopsieen aangetoond met immunofluorescen-
tie. Aile meeiresultaten werden in de tijd geplaatstten opzichte van de dag waarop 
het alanine-aminotransferase (ALI) maxirnaal was, als teken van maxirnale lever-
celbeschadiging. Zes maanden na het begin van de ziekte waren 53 patienten 
genezen en JO waren chronische HBsAg-dragers geworden. In de vroege ziekte-
periode werden bij deze !wee groepen patienten geen verschillen in virusanti-
genen waargenomen. Vanaf !wee weken voorafgaande aan de maximale ALT 
daalden de HBsAg- en de HBeAg-spiegels significant bij die patienten die 
genazen. Het verdwijnen van HBeAg en HBsAg correleerde niet met de mate van 
levercelbeschadiging. HBV-DNA, DNA-polymerase en virale antigenen in de lever-
biopsieen waren voomamelijk aantoonbaar in de periode voor en tijdens de 
maximale ALT. De virusantigenen bleven constant aanwezig in serum en lever van 
patienten die chronisch drager werden. 
Deze resultaten vormen een aanwijzing dat tijdens de acute lase van hepatitis B 
het tijdstip waarop het uiteindelijke ziektebeloop word! bepaald minstens !wee 
weken voorafgaat aan dat van het maxirnale ]evercelverval. Kwantitatieve 
bepaling van HBsAg of HBeAg kan een vroege indicator zijn van de prognose. De 
bevinding dat virale kenmerken onafhankelijk van de mate van levercelbeschadiging 
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kunnen verdwijnen suggereert dat, naast destructie van geinfecteerde levercellen, 
suppressie van de synthese van HBV-bestanddelen een dee! van het mechanisme 
van HBV-eliminatie vormt. 
In hoofdstuk N wordt de relatie besproken tussen subtypen of antistoffen tegen 
subtypen van het HBV en de ontwikkeling van de klinische beloopsvormen, 
alsmede enige aspecten van de humorale immuniteit. 
In een groep van 89 chronische HBV-dragers vanNederlandse afkomst en beho-
rend tot het Kaukasische ras werd bij 32 een gelijktijdig voorkomen van HBsAg en 
anti-HBs vastgesteld. Bij deze HBV-dragers en bij 38 patienten met een genezende 
acute hepatitis B werden het voorkomen van HBV-subtypen en de verdeling van 
risicofactoren om een HBV-infectie op te !open vergeleken. Van de 32 chronische 
HBV-dragers met anti-HBs hadden 28 HBsAg-subtype ad (HBsAg/ad) en 4 subtype 
ay (HBsAg/ay).Het subtype van anti-HBs kon bij 25 patienten worden vastgesteld. 
Bij 20 van hen kwam HBsAg/ad in combinatie voor met anti-HBs subtype anti-y. 
HBsAg/ay en anti-HBs subtype anti-d kwamen bij een patient gelijktijdig voor. Bij 
de overige 4 patienten bestond er een complex patroon. In de groep met acute 
hepatitis B hadden 25 patienten HBsAg/ay en 13 HBsAg/ad. In onze patienten-
groepen kwam dus HBsAg/ay vaker voor bij genezende acute hepatitis B en 
HBsAg/ad bij chronische HBV-dragers. Dit verschil werd gedeeltelijk veroorzaakt 
door het voorkomen van HBsAg/ay bij drug-spuiters en HBsAg/ad bij homosexuelen. 
Personen die geen drugs gebruikten hadden een gelijke kans op infectie met 
HBsAg/ad of HBsAg/ay. 
Achttien chronische HBV-dragers met anti-HBs werden gematched betreffende 
leeftijd, histologische leverafwijkingen en HBeAg-status met 18 dragers zonder anti-
HBs. In deze groepen werd geen verschillend risico op besmetting met HBV gevon-
den. Dit geeft geen steun a an de hypothese dat gelijktij dig voorkomen van HE sAg 
en anti-HBs het gevolg is van twee opeenvolgende infecties met verschillende 
HBV-subtypen. 
De frekwentie van gelijktijdig HBsAg en anti-HBs correleerde met de emstvan de 
leverzielcte: anti-HBs werd gevonden bij 3 van de 23 asymptomatische HBV-
dragers, bij 4 van de 20 patienten met chronisch persisterende hepatitis B, bij 20 
van de 41 patienten met chronisch actieve hepatitis B en bij aile 5 patienten met 
chronisch actieve hepatitis B en leverctrrose. De relatief hoge frekwentie van anti-
HBs bij patienten met een emstiger vorm van chronische hepatitis B is mogelijk het 
gevolg van een stoomis in de immunologische respons. 
In hoofdstuk V wordt het onderzoek beschreven betreffende subpopulaties van T-
lymfocyten bij verschillende beloopsvormen van hepatitis B. 
De cellulaire immuunrespons van de gastheer wordt deels gereguleerd door de 
T-helper en T-suppressor subpopulaties. Bij 97 patienten met verschillend beloop 
na HBV-infectie werden de perifere T -cel-subpopulaties bepaald: 23 asymptomati-
sche HBV-dragers zonder leverziek:te, 13 patienten met chronisch persisterende 
hepatitis B, 19 patienten met chronisch actieve hepatitis B (11 met HBeAg, 8 met 
anti-HBe), 7 patienten met chronisch actieve hepatitis en anti-HBs, en 35 personen 
met anti-HBs na genezing van acute hepatitis B. De perifere mononucleaire cellen 
werden specifiek gemerk:t met monoclonale Leu-] (T -cellen), Leu-2a (T -suppressor 
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en -cytotoxische cellen), en Leu-3a (T-helper cellen) antilichamen en geteld met 
flow-cytometrie. 
De Leu-3a/Leu-2a ratio's van chronische HBV-dragers verschilden niet van de 
ratio's van personen die het HBV hadden opgeruimd. Bij de patienten met voort-
gaande chronisch actieve hepatitis ondanks negatief HBeAg en positief anti-HBe 
werd een verlaagd aantal T -suppressor cell en gevonden. 
Deze bevindingen duiden er op dat de HBV-eliminatie niel is gerelateerd aan de 
kwantitatieve verhouding van de onderzochte T-cel-subpopulaties in het perifere 
bleed. Gezien het !age aantal T-suppressor cellen hebben patienten met voort-
gaande chronisch actieve hepatitis na gedeeltelijke opruiming van het virus 
mogelijk een toegenomen imrnuno-reactiviteit ten opzichte van de patienten die 
een meer algemeen ziektebeloop hebben. 
Hoofdstc!k VI betreft de genetische basis die mogelijk het ziektebeloop na HBV-
infectie bepaalt. 
Ten einde een correlatie te vinden tussen het ziektebeloop en de fenotype-
frequentie van HLA-deterrninanten werden 396 Nederlanders onderzocht. Allen 
behoorden tot het Noord-Europese locale Kaukasische ras. Zes groepen personen 
met verschillend ziektebeloop na HBV-infectie werden vergeleken met gezonden. 
De hepatitis B patienten werden als volgt gegroepeerd: I) 4 7 waren genezen van 
acute icterische hepatitis B, 2) 60 waren genezen van anicterische hepatitis B, 3) 26 
waren asymptomatische HBsAg-dragers, 4) 16 hadden chronisch persisterende 
hepatitis B, 5) 37 hadden chronisch actieve hepatitis Ben 6) 10 hadden chronisch 
actieve hepatitis na eliminatie van de HBV-antigenen. 29 klasse I en 13 klasse II 
HLA-antigenen werden bepaald met behulp van rnicro-lymfocytotoxiciteits-
testen. 
De fenotype-frequentie van het klasse 11-antigeen DQw 1 was significant ver-
laagd bij patienten met chronisch actieve hepatitis B. Geen andere HLA-typen 
waren statistisch significant alwijkend van de controlegroep. Er werd geen aanwij-
zing gevonden dat de elirninatie van HBV is gerelateerd aan een HLA-fenotype. 
HLA-DQw I beinvloedt mogelijk de mate van levercelbeschadiging aangezien het 
lijkt te beschermen tegen de ontwikkeling van chronisch actieve hepatitis. 
Een algemene beschrijving van het onderzoek en een bespreking van de resulta-
ten word! gepresenteerd in hoofdstuk VII. De uitgangspunten, de patientenselectie, 
de methoden en het verrichte onderzoek worden besproken in relatie tot het doe! 
van het onderzoek. 
Conclusies 
De resultaten van dit onderzoek wijzen uit dat bij de elirninatie van het HBV en de 
onlwikkeling van levercelnecrose verschillende immunologtsche mechanismen zijn 
betrokken op verschillende tijdstippen in het beloop van hepatitis B. De volgende 
conclusies worden ingedeeld ten aanzien van HBV-eliminatie en levercelbescha-
diging bij acute en bij chronische hepatitis B. 
Eliminatie van het HBV lijkt in de vroege lase van acute hepatitis B die gene est 
minslens !wee weken vooraf te gaan aan het tijdstip waarop de levercel-necrose 
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maximaal is. Bij acute hepatitis B die overgaat in chronisch HBV-dragerschap Ire-
den in de vroege lase geen tekenen op van HBV-eliminatie. Deze bevindingen vor-
men een aanwijzing dat het ziektebeloop bij acute hepatitis B reeds is vastgelegd 
voordat de klinische verschijnselen optreden. Bij de onderzochte Nederlandse 
patienten is HBsAg-subtype ad mogelijk in Iichte mate gerelateerd aan deficiente 
HBV-eliminatie. 
De levercelbeschadiging tijdens de vroege lase van acute hepatitis B vertoont 
noch in de tijd, noch wat betreft hevigheid een correlatie met de mate van HBV-
eliminatie. Dit steunt de hypothese dat virale eliminatie ( gedeeltelijk) het gevolg 
kan zijn van suppressie van de virusproductie zonder dat hiervoor levercellen wor-
den vernietigd. Niet-specifiek anti-HBs werd relatief vaker gevonden bij patienten 
met een emstiger beloop van chronische hepatitis B en lijkt beter te correleren met 
de mate van leverbeschadiging dan met HBV-eliminatie. Dit verschijnsel werd 
geinterpreteerd als teken van een kwalitatief defect van de immuunrespons op de 
HBV-infectie. Het !age aantal T-suppressor cellen dat werd gevonden bij patienten 
met voortgaande chronisch actieve hepatitis B na verdwijnen van HBeAg kan dui-
den op een verhoogde immuunreactiviteit bij deze patienten. De !age fenotype-
frequentie van HLA-DQw 1 binnen de patientengroep met chronisch actieve 
hepatitis B !a at zien dat genetische factoren mogelijk zijn betrokken bij de regulatie 
van de ernst van levercelbeschadiging. 
De bevindingen van het onderzoek dat in dit proefschrift word! beschreven kun-
nen theoretisch implicaties hebben voor de behandeling van hepatitis B. Anti-
virale rniddelen zouden een beter effect kunnen hebben indien zij in een vroege 
lase van hepatitis B worden toegediend. Herhaalde kwantitatieve bepaling van 
HBsAg of HBeAg kan van nut zijn bij de vroege identificatie van patient en met een 
potentieel chronisch beloop. De subgroep van patienten met chronisch actieve 
hepatitis B na verdwijnen van HBeAg heeft enige kenmerken van "auto-immuun" 
hepatitis en kan mogelijk zijn gebaat bij behandeling met immunosuppressiva. 
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